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One Sentence Summary: Using a brain-infiltrating T cell clone that is clonally expanded in 
multiple sclerosis brain lesions and positional scanning peptide libraries in combination with 
biometrical analysis, we have identified GDP-L-fucose synthase as a putative autoantigen that 
is recognized by cerebrospinal fluid-infiltrating CD4+ T cells from HLA-DRB3*-positive patients. 
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ABSTRACT 
Multiple sclerosis is a CD4+ T cell-mediated autoimmune disease of the central nervous system 
that develops in genetically susceptible individuals and likely requires environmental triggers. 
The autoantigen/s and molecular mimic/s triggering the autoimmune response in multiple 
sclerosis remain incompletely understood. By using a brain-infiltrating T cell clone that is 
clonally expanded in multiple sclerosis brain lesions and an unbiased approach for the 
identification of its target antigens, positional scanning peptide libraries in combination with 
biometrical analysis, we have identified GDP-L-fucose synthase as a novel autoantigen that is 
recognized by cerebrospinal fluid-infiltrating CD4+ T cells from HLA-DRB3*-positive patients. 
Significant associations were found between reactivity to GDP-L-fucose synthase peptides and 
DRB3*02:02 expression, along with reactivity against an immunodominant myelin basic protein 
peptide. These results, coupled with the cross-recognition of homologous peptides from gut 
microbiota, suggest a possible role of this antigen as inducer or driver of pathogenic 
autoimmune responses in MS. 
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INTRODUCTION 
Multiple sclerosis (MS) is considered a demyelinating autoimmune disease of the central 
nervous system (1-4). The inflammatory infiltrate in demyelinating brain lesions, the intrathecal 
production of oligoclonal immunoglobulin G, the genetic trait consisting of multiple immune-
related genes (5, 6), the positive effect of immunotherapies targeting B and T cells, and the 
similarities with the animal model experimental autoimmune encephalomyelitis, all support that 
MS is an immune-mediated disease. The dominance of CD8+ T cells in MS brain lesions and 
the predisposition conferred by the HLA-A*03:01 allele and protection by HLA-A*0201 (6, 7) as 
well as evidence in experimental animal models (8) hint at a relevant role of these cells in MS 
pathogenesis. However, the fact that the HLA-DR15 haplotype is by far the strongest genetic 
risk factor associated with MS and that immunization with myelin components induces relapsing 
or chronic demyelinating disease models, which can be transferred by myelin-specific CD4+ T 
cells to naive animals, underscore that autoreactive CD4+ T cells play a central role in MS 
pathogenesis (1). Although myelin protein/peptides are considered relevant autoantigens in MS 
(9), the full spectrum of target antigen(s) driving the immune response in this disease has yet to 
be defined. 
The etiology of MS involves both a complex genetic trait with more than 100 quantitative trait 
loci (5, 6) and several environmental risk factors including vitamin D, smoking (10), viral 
infections (11) and gut microbiota (12). Several studies have reported distinct fecal microbial 
community profiles in MS patients compared to healthy controls (13-16), which might affect 
autoimmune responses by regulating permeability of the blood brain barrier (BBB), by 
modulating the maturation, activation and function of immune cells (12, 15-17), or by controlling 
the maturation and function of microglia (18) and astroglia (19). In order to be able to cross the 
BBB and infiltrate the brain, autoreactive T cells first have to be activated outside the CNS. 
Cross-reactivity between autoantigens and peptides from pathogens or gut microbiota, i.e. 
molecular mimicry, has been considered a putative trigger of the autoimmune reaction in MS. 
The identification of autoantigen/s and molecular mimic/s targeted by pathogenic CD4+ T cells 
in MS may improve our understanding of disease mechanisms, help in diagnostic classification 
of MS patients and enable the development of antigen-specific immunotherapies (20). In the 
past, the search for candidate autoantigen/s in MS has concentrated on myelin components 
based on the fact that demyelination is a hallmark of MS brain lesions. Furthermore, 
immunological research in MS patients focused on studying myelin-specific T cells from the 
peripheral blood, since the target tissue, i.e. brain and spinal cord, is rarely available for 
immunological studies. Autoimmune diseases like primary biliary cirrhosis can be exquisitely 
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organ- or tissue-specific, and nevertheless T cell autoreactivity be directed against ubiquitous 
autoantigens such as pyruvate dehydrogenase (21). Thus, the focus on myelin-specific CD4+ T 
cells and on cells circulating in the peripheral blood has had limitations in the search for 
candidate autoantigen/s and molecular mimic/s in MS. Non-myelin target antigens should 
therefore also be considered in MS. To overcome these limitations, we (a) applied the unbiased 
identification of stimulatory peptides using positional scanning peptide libraries (22, 23) and 
biometrical analysis (24, 25), and (b) concentrated on putatively disease-relevant T cells that 
infiltrated brain lesions and were clonally expanded locally. We focused on T cell clone (TCC) 
21.1, a CD4+ TCC that was identified in active pattern II demyelinating brain lesions from a 
secondary progressive (SP) MS patient using deep T cell receptor (TCR) β-chain sequencing 
and that was isolated from autologous cerebrospinal fluid (CSF)-infiltrating cells as previously 
described (26). The release of Th2 cytokines and the ability to help B cells (26) supports a 
pathogenic role of this TCC in pattern II demyelination that is mediated by antibodies and 
complement (27). Using the above methodological approach, we have identified GDP-L-fucose 
synthase as the main specificity of TCC21.1. Reactivity against this protein as well as against 
myelin and putative molecular mimic/s has then been examined more broadly in CSF-infiltrating 
CD4+ T cells from MS patients and led to the identification of a novel target autoantigen in MS.  
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RESULTS 
Peptide mixtures to identify the specificity of a brain-infiltrating TCC 
TCC21.1 is a CD4+ TCC isolated from CSF-infiltrating cells and clonally expanded in two active 
white matter demyelinating MS lesions (LI and LIII) from a SPMS patient (1154SA) with pattern 
II demyelination (26). TCC21.1 releases Th2 cytokines and helps proliferation and antibody 
production by autologous B cells upon unspecific activation. TCR α- and β-chain sequences of 
TCC21.1 are: TRAV12-2, TRAJ42*01, CDR3α CAVNEGSQGNLIF and TRBV11-2*01, TRBJ1-
2*01, TRBD1*01, CDR3β CASSGRGPSYGYT, respectively. In order to study the peptides 
recognized by this TCC of unknown specificity using a decapeptide positional scanning library, 
we first identified the HLA class II molecule used by TCC21.1 to recognize the peptide mixtures 
(28). Since patient 1154SA was homozygous for the DR15 haplotype, we tested TCC21.1 
initially only with the mixtures with amino acids (AAs) defined at position 5, presented by EBV 
immortalized BLS B cells (BCL) transfected with different single autologous HLA DR/DQ 
molecules (DRA*01:01/DRB5*01:01, DRA*01:01/DRB1*15:01 and DQA1*01:02/DQB1*06:02).  
As readout of T cell activation we used GM-CSF production (29), since TCC21.1 releases this 
cytokine after unspecific stimulation with anti-CD3 and PMA (26). Only mixtures presented by 
BCL expressing DRB1*15:01 class II molecules were stimulatory (Fig. 1A). We then tested 
TCC21.1 with the complete decapeptide positional scanning library (200 mixtures), presented 
by BCL expressing DRB1*15:01 class II molecules. GM-CSF release in response to the 
complete library is shown in Fig. 1B (black histograms). Next, we generated a biometrical 
analysis scoring matrix by assigning numerical values to the stimulatory potential of each of the 
20 defined AAs in each of the ten positions of the decapeptide library as previously described 
(24). Here, the values were calculated as the log base 10 of the median GM-CSF (pg/ml) 
secretion of three independent experiments in the presence of mixtures, minus the secretion in 
the absence of mixtures (Fig. 1C). Based on a model of independent contribution of individual 
AAs to peptide antigen recognition, the predicted stimulatory score of a given peptide is the sum 
of the matrix values of each AA contained in the peptide at each position (24). This scoring 
approach was applied to rank, according to their stimulatory score that is predictive of their 
stimulatory potency, all natural overlapping 10-mers peptides of the protein sequences within 
the UniProt human protein database (30). Based upon these predicted values, we synthesized 
and tested at 5 µg/ml the 50 predicted human natural peptides with highest scores (Table S1). 
Unexpectedly, none of the peptides was clearly stimulatory (Fig. 1D). The predictive capacity of 
the above approach combining positional scanning library and biometrical analysis was lower 
for this TCC than for others in previous studies (25). 
To further explore this unusual discrepancy between the mixture activities and the lower than 
expected activity of the peptides described above, we first noted that TCC21.1 also released 
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high levels of IL-10 after unspecific stimulation with anti-CD3 and PMA (26). TCC21.1 was then 
tested with the complete decapeptide positional scanning library using IL-10 production as 
readout (Fig.1B, white histograms). A similar but not identical response pattern was obtained 
with both readouts. The most stimulatory mixtures with both approaches are shown in Fig. 1C. 
Interestingly, these mixtures have identical defined AAs in consecutive positions, suggesting a 
possible recognition of one AA motif in multiple frames. To confirm this observation, a set of 22 
dual-defined mixtures (i.e. positional scanning mixtures with two defined positions) was 
designed, synthesized, and tested (Fig. 1E); the results confirmed the presence of a unique 
recognition motif (LHSXFEV) with different flanking residues (Fig. 1F). In order to apply this 
recognition motif in the two frames to the original GM-CSF-derived matrix and perform 
biometrical analysis, we used the harmonic mean model (HM) (31) to integrate the stimulatory 
responses of some of the dual defined mixtures (Fig. 1E, Frame 1/2-HM mixtures) into the 
original matrix (Fig. S1). Using the new “harmonic boost” frame 1 and frame 2 matrices, all 
natural overlapping 10-mers peptides in the protein sequences within the UniProt human 
database were scored and ranked as before. The 50 predicted natural peptides with highest 
scores for both matrices were synthesized and tested for GM-CSF release (Table S1). These 
two matrices allowed us the identification of three clearly stimulatory peptides (Fig. 1G). The two 
most stimulatory peptides, NVLHSAFEVG predicted with harmonic boost frame 1 and 
DNVLHSAFEV predicted with harmonic boost frame 2, belong to GDP-L-fucose synthase 
encoded by the TSTA3 gene, and overlap by 9 AAs. The third stimulatory peptide 
(KLLLHSGVEN) was predicted with harmonic boost frame 2 and belongs to a transmembrane 
protein (FLJ37396). 
GDP-L-fucose synthase as the main autoantigen for a brain-infiltrating TCC 
In order to identify autoantigens recognized by TCC21.1 in the two autologous brain lesions 
within which TCC21.1 was known to be clonally expanded (LI and III (26)), the harmonic boost 
frame 1 and frame 2 matrices were then used to score and rank, according to their stimulatory 
score, all natural overlapping 10-mer peptides in the protein sequences within a brain-protein 
sub-database created with RNASeq-based transcriptome data from these two lesions 
(GSE60943). Of the 40 predicted natural brain peptides with highest scores for the frame 1 
matrix, 38 peptides were already predicted from the unbiased UniProt human database. For 
frame 2 matrix, the top 40 peptides were previously predicted (Table S1). The two new peptides 
for frame 1 were synthesized and tested. NVLHSAFEVG (GDP-L-fucose synthase 96-105) and 
DNVLHSAFEV (95-104) were the only peptides from proteins transcribed in autologous brain 
lesions found to stimulate TCC21.1 (Table S1). 
Transcript level, expressed as reads per kilo base of exon model per million mapped reads 
(RPKM), of GDP-L-fucose synthase in the autologous brain LI and LIII is shown in Table 1. 
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Transcript values for other brain-specific genes are also shown as quality control of the samples 
and as reference for genes expressed at high (myelin basic protein (MBP), myelin proteolipid 
protein 1 (PLP1)), and medium (myelin-associated glycoprotein (MAG), myelin-associated 
oligodendrocyte basic protein (MOBP) and oligodendrocyte myelin glycoprotein (OMG)) level. 
Seventeen GDP-L-fucose synthase peptides were identified in white and grey matter brain 
tissue from other MS patients and non-MS controls by proteomic analysis. The peptide 
sequences are listed in Table 1 as well as the peptide spectrum matches (PSM) in the different 
samples. The percentage of the GDP-L-fucose synthase AA sequence covered by identified 
peptides was 56%. Analysis of other brain-specific proteins as reference is also included (Table 
1 and Table S3). 
Characterization of GDP-L-fucose synthase recognition by a brain-infiltrating TCC 
As mentioned above, the two GDP-L-fucose synthase peptides recognized by TCC21.1 overlap 
by 9 AAs. We synthesized and tested on DRB1*15:01-expressing BCL nine additional 10-mer 
peptides overlapping by 9 AAs and identified an additional peptide, VLHSAFEVGA (97-106), 
which induced GM-CSF release (Fig. 2A). Peptide NVLHSAFEVG (96-105) gave the optimal 
response with an EC50 of 0.2 µg/ml (Fig. 2B) and was presented by DRB1*15:01 and 
DQB1*0602 molecules (Fig. 2C). As we demonstrated previously, the cross-reactivity and 
cross-restriction of TCC21.1 might facilitate its activation (32, 33). The common AAs of the three 
stimulatory GDP-L-fucose synthase peptides are VLHSAFEV (97-104).  Single alanine (A) 
substitutions of these three overlapping peptides revealed that the substitution of H99 and S100 
abrogated the T cell responses, suggesting that they are the primary AA involved in TCR or 
HLA interaction. The substitution of V97, L98, F102 or E103 for A in the most active peptide 
NVLHSAFEVG (96-105) resulted in peptides with some stimulatory activity, in contrast to the 
two other overlapping peptides in which their substitution resulted in non-stimulatory peptides. 
Thus the residues V97, L98, F102 and E103 appear to be secondary TCR or HLA contacts (Fig. 
2D). 
Next, we characterized the response of TCC21.1 to GDP-L-fucose synthase peptides presented 
by autologous irradiated peripheral blood mononuclear cells (PBMCs) and BCL. GDP-L-fucose 
synthase peptides presented by the two types of APCs were able to induce proliferation, 
although PBMCs were more efficient (Fig. 2E). We also analyzed the functional phenotype of 
this response (Fig. 2E). TCC21.1 displayed a Th2 phenotype, releasing mainly Th2 cytokines 
and lower levels of IL-22 and IL-10. Unexpectedly, when peptides were presented by 
autologous BCL, they induced higher levels of IFNγ. In addition, TCC21.1 also released GM-
CSF and IL-3 in response to GDP-L-fucose synthase peptides (Fig. 2F). The release of these 
two cytokines seems to be a specific feature of this TCC compared with other Th1, Th1* or 
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Th1/2 TCCs that our laboratory had generated from patients with different conditions. 
Intracellular cytokine staining confirmed the Th2 functional phenotype of TCC21.1 in response 
to GDP-L-fucose synthase (96-105) (Fig. 2G). More than 60% of TCC21.1 cells were IL-4+ after 
stimulation with GDP-L-fucose synthase (96-105), while only around 12% were IFNγ+. Around 
60% of the cells were GM-CSF+ and 47.7% of these also IL-4+. Further characterization of 
TCC21.1 demonstrated expression of CD28 and the chemokine receptor CRTh2 (Fig. 2H). 
Recognition of GDP-L-fucose synthase by CSF-infiltrating CD4+ T cells from patient 
1154SA 
Sixty-two 15-mer peptides overlapping by 10 AAs and covering the entire GDP-L-fucose 
synthase protein (Table S2) were synthesized and tested for their ability to induce TCC21.1 
proliferation when presented by autologous PBMCs. Seven immunodominant/encephalitogenic 
myelin peptides (34), CEF (cytomegalovirus, EBV, influenza virus and tetanus toxoid) peptide 
pool and control beads were tested in parallel (Table S2 and Fig. 3A). TCC21.1 only recognized 
two overlapping GDP-L-fucose synthase peptides, 91-105 and 96-110, containing the three 
stimulatory decapeptides (95-104, 96-105 and 97-106) that we identified previously. Bulk CSF-
infiltrating CD4+ T cells after short and long phytohaemagglutinin (PHA) expansion (see M&M) 
were tested with the GDP-L-fucose synthase-, myelin- and CEF peptides (Fig. 3A). Long- but 
not short-PHA-expanded CSF-infiltrating CD4+ T cells proliferated in response to three GDP-L-
fucose synthase peptides suggesting a low frequency of specific TCCs in the initial CSF 
infiltrate and a preferential expansion with enrichment of some TCCs, including TCC21.1, during 
the long PHA expansion. Proliferation of long-PHA-expanded CSF-infiltrating CD4+ T cells to 
peptides 91-105 and 96-110 was mainly mediated by TCC21.1 since Vb21+ (that included 
TCC21.1) but not Vb21- CSF-infiltrating CD4+ T cells proliferated in response to this peptide 
(Fig. 3B). Interestingly, the third GDP-L-fucose synthase peptide recognized by long-PHA-
expanded CSF-infiltrating CD4+ T cells (191-205) was not recognized by TCC21.1 (Fig. 3A). We 
generated a T cell line (TCL) from these proliferating cells (TCL39, Fig. 3C), and its TCR 
sequencing confirmed the existence of three TCCs other than TCC21.1. Although we have not 
been able to identify the TCC responsible for GDP-L-fucose-specific response, it is interesting 
to note that two of these TCCs were clonally expanded in active brain lesion III and ranked in 
positions 51 and 56 regarding their frequency (Fig. 3D (26)). Functional phenotype analysis of 
responses to peptides 91-105 and 191-205 showed a Th2 response for peptide 91-105, 
confirming activation of TCC21.1, but a Th1/Th2 response for peptide 191-205 supporting 
activation of other TCCs (Fig. 3E). Bulk CSF-infiltrating CD4+ T cells did not recognize either the 
myelin peptides or the CEF peptide pool. 
Recognition of GDP-L-fucose synthase by CSF-infiltrating CD4+ T cells from CIS/MS 
patients. 
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In order to find out how frequently specific recognition of GDP-L-fucose synthase occurs in 
CSF-infiltrating CD4+ T cells in CIS/MS patients, we developed a new protocol to expand fresh 
CSF-infiltrating CD4+ T cells to high numbers in a single round to minimize variations in the 
original T cell repertoire (see M&M). Resting PHA-expanded CSF-infiltrating CD4+ T cells from 
31 CIS/MS patients were tested in quadruplicate with the 62 overlapping GDP-L-fucose 
synthase peptides presented by autologous irradiated PBMCs, as well as with the seven myelin 
peptides, CEF peptide pool and control beads. All SIs (except control beads) were pooled and 
SI values less than one were treated as having unit value. Cluster k-means analysis was 
performed to determine the optimal cut-off to differentiate responsive SI values from non-
responsive in this patient population. K-means clustering resulted in a cut-off value of 1.455 to 
differentiate positive responses from negative. Subsequently, for each patient, all peptides 
having a median SI (of the quadruplicate wells) greater than 1.455 were identified as positive 
responses (Table S4A). Notably, a follow-up study of the negative control well SI values using 
Monte-Carlo bootstrapping indicated that the 1.455 cut-off showed a 0.26% false positive rate 
when applied to simulated medians of quadruplicate negative values. 
Next, patient scores were constructed by calculating the sum of each responsive peptide 
median SI, weighted by the number of total patients that responded to that peptide.  In this way, 
both the SI values themselves for each peptide, as well as the relative immunogenicity of each 
peptide, were factored in. Three-cluster k-means analysis was performed on base 10 patient 
scores and clearly grouped patients into three categories: “nonresponders”, “moderate 
responders”, and “high responders” (Table S4A). Nineteen patients (61.3%) were therefore 
characterized as nonresponders to GDP-L-fucose synthase (Fig. S2A), six (19.35%) as 
moderate, and six (19.35%) as high responders (Fig.4A). No significant differences between the 
three groups were found for CEF responses or for the positive or negative controls (Fig. S2B). 
Immunodominant peptides were defined as peptides able to induce positive responses in at 
least three patients. The 14 GDP-L-fucose peptides achieving this criterion are shown in Figure 
4B. Functional analysis of the strongest responses to some immunodominant peptides revealed 
a Th1 phenotype with mainly production of IFNγ (Fig. 4C). 
T cell responses to immunodominant GDP-L-fucose synthase peptides are associated 
with reactivity against MBP 83-99 
In order to judge better the reactivity of CSF-infiltrating CD4+ T cells in CIS/MS patients against 
GDP-L-fucose synthase peptides, we compared it with reactivity against the seven 
immunodominant/encephalitogenic myelin peptides, which had previously been shown to be the 
targets of high avidity T cells in MS (34) (Fig.5A). Four out of six (67%) of the high responder 
patients to GDP-L-fucose synthase also responded to myelin peptides, while only one of the six 
(17%) moderate responders and two of the 19 (11%) nonresponders did (Fig.5A). This 
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association is significant (p=0.0138, Fisher’s exact test). When comparing the recognition of 
immunodominant GDP-L-fucose synthase peptides and specific myelin peptides (Fig.5B), we 
found a significant association between recognition of peptide MBP 83-99 and three 
immunodominant GDP-L-fucose synthase peptides (1-15 – p=0.0122, 156-170 – p=0.0122, and 
256-270 – p=0.0481, Fisher’s exact tests with Bonferroni-Holm correction) (Fig.5B). 
T cell response to GDP-L-fucose synthase is associated with DRB3* alleles 
Table 2 summarizes demographical and clinical characteristics of the CIS/MS patients and their 
designation as nonresponders, moderate responders, or high responders to GDP-L-fucose 
synthase peptides. No significant differences between groups could be identified regarding 
disease course or clinical presentation, gender, age, CSF IgG index or number of CSF-
infiltrating cells. HLA class II typing is also summarized in Table 2. Interestingly, all six of the 
high responder patients are DRB3*02:02, while only one of the six (17%) moderate responders 
and four of the 19 (21%) nonresponders express this class II molecule. This association is 
significant (p=0.0006, Fisher’s exact test). Further, when looking only at the difference between 
moderate responders and nonresponders, an additional significant association was observed; 
three of the six (50%) moderate responders are DRB3*01:01 while only one of the 19 (5%) 
nonresponders is (p=0.0312, Fisher’s exact test). The predicted binding affinities of positive 
peptides to DRB3*01:01 and DRB3*02:02 are summarized in Table S4B. 
Cross-recognition of human and bacterial GDP-L-fucose synthase peptides by CD4+ CSF-
infiltrating T cells 
GDP-L-fucose synthase is a cytosolic enzyme that converts GDP-4-keto-6-deoxy-D-mannose 
into GDP-L-fucose that then is used to fucosylate oligosaccharides (35) including sugars and 
glycoproteins on mucosal intestinal cells. Gut microbiota use a mammalian-like pathway of 
fucosylation to colonize the mammalian intestine (36). GDP-L-fucose synthase is an 
evolutionarily conserved protein (37). In order to search for molecular mimics that might induce 
or perpetuate GDP-L-fucose synthase-specific T cells, we therefore compared the protein 
sequence of human GDP-L-fucose synthase with several bacterial GDP-L-fucose synthase 
sequences. We focused on bacterial species that have been reported to be altered in gut 
microbiota of MS patients and for which GDP-L-fucose synthase sequences were available, 
further on bacterial species present in gut microbiota without association with MS, and also 
some pathogens not present in gut (Table S5). Sequence comparison of the four main 
immunodominant peptides is shown in Table S6A.  The most immunodominant human GDP-L-
fucose synthase peptide, 161-175, showed the highest homology with bacterial sequences, and 
particularly with those associated with MS, with which it shares at least 40% homology. Eight 
15-mer bacterial peptides with at least 40% homology with the human 161-175 peptide and 
GDP-L-fucose synthase as putative autoantigen in MS 	  
	   11	  
shared by different bacteria species were synthesized as 15- and 10-mer (overlapping in 5 AAs) 
peptides (Table S6B). Reactivity of CSF-infiltrating CD4+ T cells against these bacterial peptides 
was tested in eight CIS/MS patients. Six of these patients were patients from our previous 
cohort from whom autologous PBMCs were available (748UR, 1005ME, 1129RE, 1173DI, 
718MA and 776JE). Five of them (748UR, 1129RE, 1173DI, 718MA and 776JE) had a positive 
response to human peptide 161-175, while patient 1005ME did not respond to this peptide and 
was included as control (Fig. 4A). Two additional patients (1440AM and 1489HE), from whom 
autologous PBMCs were not sufficient to test all GDP-L-fucose synthase peptides and who 
were not included in the previous cohort, were also identified as high responders to GDP-L-
fucose synthase peptides, including peptide 161-175, after testing with a selection of six 
immunodominant peptides (Fig. S3A). Both patients were also DRB3* (Fig. S3B). 1489HE was 
DRB3*02:02 and 1440AM expressed DRB3*03:01 with high homology with DRB3*02:02 (38). 
CD4+ CSF-infiltrating T cells from four of these patients (1489HE, 1173DI, 748UR and 776JE) 
proliferated in response to different bacterial peptides (Fig. 6). Interestingly, the four patients 
showed reactivity against peptides 3 and 4, which show the highest degree of homology 
(53,3%) with the human peptide (Fig. 6). Blast (NCBI) analysis of these bacterial peptides (Fig. 
S3C) revealed that peptide 3 was shared by bacteria from the genera Akkermansia and 
Prevotella, which both have been reported to be altered in MS patients (14). Peptide 4 is also 
shared by different bacterial genera present in gut microbiota and belonging to the phylum 
Bacteroidetes, the second most abundant phylum, after Firmicutes, in gut microbiota.  
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DISCUSSION 
Assuming that MS is a CD4+ T cell-mediated autoimmune disease it is crucial to elucidate the 
target antigens responsible for inducing CD4+ T cell activation to understand MS pathogenesis. 
In addition, it is a prerequisite for developing antigen-specific tolerization strategies. Using 
positional scanning peptide libraries in combination with biometric analysis, we have identified 
GDP-L-fucose synthase as the main specificity of TCC21.1, a brain-infiltrating and clonally 
expanded TCC from a SPMS patient with pattern II demyelination (26). In pattern II lesions, 
demyelination is mediated by deposits of antibody and complement in addition to macrophages 
and T cells (27). TCC21.1, in addition to be clonally expanded in active MS lesions, was able to 
release Th2 cytokines and help B cells after unspecific activation, characteristics that strongly 
support its putative pathogenic role in pattern II demyelination. Here, we confirmed a clear Th2 
functional phenotype of TCC21.1 in response to GDP-L-fucose synthase peptides presented by 
autologous PBMCs and the expression of the chemokine receptor CRTh2, a marker of human 
Th2 cells. Furthermore, in response to GDP-L-fucose synthase peptides, TCC21.1 also 
released GM-CSF, which is considered relevant in MS pathogenesis (39, 40), and IL-3, reported 
to promote Th2 responses (41, 42). Reactivity against GDP-L-fucose synthase peptides was 
also identified in bulk CSF-infiltrating CD4+ T cells from the same patient after long but not short 
PHA expansion. TCC21.1 and at least one other GDP-L-fucose synthase-specific CD4+ TCC 
were responsible for this response further supporting a putative role of GDP-L-fucose synthase 
as autoantigen. The inability to detect GDP-L-fucose synthase-specific CSF-infiltrating CD4+ T 
cells after short PHA expansion suggests a low frequency of these cells in the CSF. The fact 
that TCC21.1 and most likely also the TCC specific for peptide 191-205 were clonally expanded 
in the most active lesion III (26) suggests that these TCCs might be retained in the brain 
parenchyma and recirculate through the CSF compartment to a limited extent. The long PHA 
expansion that we performed to obtain sufficient cell numbers to isolate brain-infiltrating clonally 
expanded TCCs (26) resulted in enrichment of some TCCs that allowed us to identify at least 
one additional CSF-infiltrating TCC specific for GDP-L-fucose synthase. 
The identification of TCC21.1 specificity using positional scanning libraries was less efficient 
than in previous studies (23, 25) due to recognition by this TCC of peptides with identical 
binding/contact motif but variable flanking C- and N-terminal AA. MHC-class II molecules have 
open binding grooves and are able to present peptides with a highly variable length rendering 
TCR binding very flexible (43). However, at present it is unclear why the recognition of a TCR 
motif in different frames influenced the results for TCC21.1 more so than other TCCs. Further 
development of quantitative approaches to both detect and account for frame shifting within 
scoring matrices based on the results of TCC21.1 are currently in development. The number of 
stimulatory peptides identified for TCC21.1 was unusually low compared with previous studies 
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(23, 25). The limited cross-reactivity of TCC21.1 might underlie the special features of this TCC 
recognition profile of the decapeptide positional scanning library. 
Analysis of bulk CSF-infiltrating CD4+ T cells from other CIS/MS patients after a single PHA 
expansion demonstrated reactivity against GDP-L-fucose synthase in 40% of patients. Fourteen 
immunodominant peptides were identified that unexpectedly induced a Th1 response excluding 
a firm association between GDP-L-fucose synthase reactivity and pattern II demyelination. 
Interestingly, a significant association between recognition of GDP-L-fucose synthase and 
myelin has been found between the immunodominant GDP-L-fucose synthase peptides 1-15, 
156-170 and 256-270 and the myelin peptide MBP 83-99, and all patients reacting to both GDP-
L-fucose synthase peptides and MBP 83-99 were high responders. The putative cross-
recognition of these peptides by CSF-infiltrating CD4+ T cells might play a relevant role in MS 
pathogenesis, since CD4+ T cells specific for MBP 83-99 not only are able to induce a 
demyelinating disease similar to MS in experimental animal models, but also to exacerbate the 
human disease (44-48). Further studies are needed to determine whether single TCCs are able 
to cross-recognize MBP 83-99 and GDP-L-fucose synthase peptides, whether the recognition of 
one of these peptides facilitates the release of the other and the novo activation of new 
autoreactive T cells, a phenomenon known as epitope spreading (49), or whether these 
responses co-develop from as yet unknown reasons. 
HLA typing of the CIS/MS patients demonstrated reactivity against GDP-L-fucose synthase in 
DRB3*-positive patients and particularly strong reactivity in those expressing DRB3*02:02. The 
HLA DRB1*03 and the DRB3* haplotype most likely appeared via gene duplication of a 
common DRB1* gene in that locus, and in consequence DRB3* has been considered a 
secondary redundant locus (50). However, the ability of DRB3* molecules to present a distinct 
pattern of peptides and the existence of DRB3*-restricted T cells in peripheral blood have been 
demonstrated (51). Here, we found that the GDP-L-fucose synthase peptide 51-65, the only 
peptide stimulatory in all high responder DRB3*02:02 patients, showed the highest predicted 
binding affinity to this class II molecule, suggesting DRB3*02:02-restricted T cell recognition of 
this peptide. The DRB3*02:02 allele has been associated with MS in Korean children (52) and 
also with neuromyelitis optica (NMO) (53). Interestingly, DRB3*02:02 was over-represented in a 
cohort of NMO patients, in whom aquaporin 4-specific T cells cross-recognized a peptide from 
Clostridium perfringens, a normal component of gut microbiota (54).  
The cytosolic enzyme GDP-L-fucose synthase converts GDP-4-keto-6-deoxy-D-mannose into 
GDP-L-fucose, which is then used by fucosyltransferases to fucosylate all oligosaccharides 
(35). Synthesis of GDP-L-fucose from free L-fucose represents a minor route. In mammals, 
fucosylated glycans play important roles in many biological processes including blood 
transfusion reactions, host-microbe interactions, and cancer pathogenesis (55, 56). Fucosylated 
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glycans are highly expressed in brain tissue, and quantitative glycan profiling of human CNS 
myelin demonstrated an unusually rich variety of Lewis-type antigen containing fucosylated 
glycans compared with other tissues (57). Brain fucosylated glycans have been implicated in 
the molecular mechanisms that underlie neuronal development, survival and function (55, 58-
60) as well as in modulating immune responses. The encephalitogenic MOG is decorated with 
fucosylated glycans that support recognition by DC-SIGN on microglia and DCs. This 
recognition results in a tolerogenic signal characterized by IL-10 secretion and decreased T cell 
proliferation, while reduced fucosylation results in immunogenic signals (57). Reduction of brain 
fucosylated glycans as a consequence of T cell reactivity against GDP-L-fucose synthase might 
directly affect neurons and facilitate MS development by inducing a pro-inflammatory immune 
response. Fucosylated glycans are highly expressed also in gut tissue, where they play a 
crucial role in the host-microbe interaction (61). Fucosylation is less common in prokaryotic 
organisms, and it seems to be involved in adhesion, colonization, and regulation of the host 
immune response. In addition, a putative role of fucosylated glycans as mechanism to mimic the 
host and evade the immune system has been suggested in these organisms (56). Such a 
mechanism might be very beneficial for pathogens colonizing highly fucosylated tissues like the 
gut. In this context, the putative cross-reactivity of human and gut microbial GDP-L-fucose 
synthase peptides may represent a new role of gut microbiota in MS pathogenesis. Supporting 
this hypothesis, we demonstrated that CSF-infiltrating CD4+ T cells from four CIS/MS patients 
that were reactive against the human GDP-L-fucose synthase peptide 161-175 also recognized 
two gut microbial GDP-L-fucose synthase peptides from bacterial genera that have been 
associated with MS (13-16, 62-65) and that in addition showed the highest homology with the 
human peptide. However, since demonstration of cross-reactivity at single TCC level is missing, 
further investigation is required to clarify the putative involvement of gut-microbiota via this 
mechanism in MS pathogenesis. Recently, molecular mimicry between a specific β-cell 
autoantigen and a bacteroides integrase peptide has been demonstrated in mice. Diabetogenic 
CD8+ T cells specific of the pancreatic peptide were able to cross-recognize the microbiota 
derived peptide and suppress colitis (66). 
In conclusion, using positional scanning peptide libraries and biometrical analysis we identified 
GDP-L-fucose synthase as the main specificity of a brain-infiltrating clonally expanded TCC 
most likely involved in MS pathogenesis. This putative autoantigen is widely recognized by 
CSF-infiltrating CD4+ T cells from DRB3*-positive MS patients. The significant correlation 
between myelin and GDP-L-fucose synthase reactivity in DRB3*02:02 patients as well as the 
putative cross-recognition of homologous peptides from gut microbiota, support a role of this 
antigen as potential inducer or driver of relevant immune responses in MS. Further studies are 
needed to confirm the existence of DRB3*02:02-restricted TCCs able to cross-recognize myelin, 
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human and bacterial GDP-L-fucose synthase peptides that might provide the basis for a role of 
molecular mimicry in the development of MS. 
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MATERIAL AND METHODS 
Patient Material 
Patient 1154SA: CSF-derived mononuclear cells and PBMCs were obtained from a SPMS 
patient with pattern II demyelinating lesions as previously described (26). HLA-class I and II 
types of this patient were: A*32:01, A*33:01, B*14:02, B*51:01, DRB1*15:01, DRB5* 01:01, 
DQB1*06:02 and DQA1*01:02. 
CSF from diagnostic lumbar puncture and paired peripheral blood were collected from 31 
untreated MS patients: 8 patients with clinically isolated syndrome (CIS), 20 patients with 
relapsing-remitting (RR) MS and 3 patients with SPMS. Demographical and clinical 
characteristics of the patients are summarized in Table 2. Patients were recruited from the inims 
outpatient clinic and day hospital at the University Medical Center Hamburg-Eppendorf and the 
nims section, Neurology Clinic, University Hospital Zurich. MS diagnosis was based on the 
revised McDonald criteria (67). All CIS patients had CSF-specific oligoclonal bands detected by 
isoelectric focusing (IEF). Patients, who had not received steroids at least 4 weeks prior to 
enrolment or any immunomodulatory or immunosuppressive agent during the last 3 months, 
were considered untreated and included in the study. Fresh CSF cells from these patients were 
expanded in vitro (see below). PBMCs were freshly isolated from EDTA-containing blood tubes 
by Ficoll density gradient centrifugation (PAA, Pasching, Austria) and cryopreserved. 
The Ethik Kommission der Ärztekammer Hamburg, protocol No. 2758 and the Cantonal Ethical 
Committee of Zurich, EC-No. of the research project 2013-0001, approved the study 
procedures. Informed consent was obtained from all patients or relatives. 
Brain autopsy tissue from 13 MS patients (7 SPMS, 5 primary progressive (PP) MS and 1 
primary relapsing (PR) MS) and 7 non-MS controls were obtained from the UK Multiple 
Sclerosis Tissue Bank (UK Multicentre Research Ethics Committee, MREC/02/2/39). 
Demographical and clinical characteristics of MS patients and non-MS controls are summarized 
in Table S7. 
Transcriptomic and Proteomic Analysis 
Transcriptomic analysis of brain lesions was performed as previously described (26). The data 
discussed in this paper was deposited in NCBI's Gene Expression Omnibus and are accessible 
through GEO Series accession number GSE60943. 
For proteomic analysis, pressure-assisted protein extraction was performed with a barocycler 
(2320EXT, BioSciences, Inc, South Easton, MA) (68). Reduction and alkylation was applied on 
the homogenate before samples were digested with Lys-C and trypsin. Peptides were desalted 
on solid phase extraction columns (C18 Finisterre, Wicom Germany), vacuum dried, re-
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dissolved and measured (Nanodrop 1000, spectrophotometer (Thermo Scientific, Wilmington, 
DE, USA). Resulting peptides were purified and separated by hydrophilic interaction 
chromatography (HILIC, Agilent LC1200 equipped with a column Polyamin II 250 x 3.0 mm 120 
Å, 5µm) before they were injected on a nano liquid chromatography system Easy-nLC linked to 
an Orbitrap Fusion instrument (Thermo Fisher). Data analysis was performed with MASCOT 
software using a human UniProtKB/Swiss-Prot protein database (March 22, 2016 with 40912 
entries). Search parameters were 0.05 Da fragment mass tolerance and 10ppm precursor 
mass, minimal number of peptides 2, and FDR (false discovery rate) of 0.1%, allowing 2 mis-
cleavages on trypsin fragments. Carbamidomethylation at cysteine was set as a fixed 
modification, and oxidation of methionine, n-terminal acetylation as variable modifications. 
Positional Scanning Peptide Libraries and Individual Peptides 
A synthetic N-acetylated, C-amide L-amino acid (AA) decapeptide combinatorial library in a 
positional scanning format (200 mixtures) and twenty-two dual defined mixtures were prepared 
as previously described (69). Individual peptides (Table S1 and S2) were synthesized by 
Peptides and Elephants GmbH (Potsdam, Germany). 
Cells and culture conditions 
Bulk CSF-derived mononuclear cells from patient 1154SA were expanded as previously 
reported (26). Briefly, 2000 cells per well were seeded in 96-well U-bottom microtiter plates 
together with 2 x 105 allogeneic irradiated PBMC (45 Gy), 1 µg/ml of PHA-L (Sigma, St Louis, 
MO) and IL-2 supernatant (500 U/ml) (IL-2 hybridoma kindly provided by Dr. Sallusto, Institute 
for Research in Biomedicine, Bellinzona, Switzerland). Medium consisted of IMDM (PAA) 
containing 100 U/ml penicillin/streptomycin (PAA), 50 µg/ml gentamicin (BioWhittaker, 
Cambrex), 2 mM L-glutamine (Gibco, Invitrogen, Carlsbad, CA) and 5% heat-decomplemented 
human serum (PAA). Additional IL-2 was added every 3-4 days. After two weeks, cells were 
pooled (short expansion) or expanded by eight rounds of restimulation. In each round, 2000 
PHA-pre-expanded cells per well were seeded in 96-well U-bottom microtiter plates together 
with 2 x 105 allogeneic irradiated PBMC, PHA-L and IL-2. IL-2 was added every 3-4 days. After 
16 weeks, eight rounds of two weeks, cells were pooled (long expansion). CSF-infiltrating CD4+ 
T cells were positively selected from short and long PHA-expanded bulk CSF-derived cells 
using anti-CD4 magnetic beads (CD4 Micro Beads human MACS, Miltenyi Biotec Inc, CA, USA) 
and restimulated once again with PHA-L, IL-2 and allogeneic irradiated PBMC.  
TCC21.1 was established from CSF-infiltrating cells as previously described (26). TCL-39 was 
generated from CSF-derived CD4+ T cells (long PHA expansion) that responded to GDP-L-
fucose synthase peptide 191-205. Positive wells underwent five rounds of restimulation with 
PHA and allogeneic irradiated PBMCs and IL-2. Additional IL-2 was added every 3-4 days. 
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The approach used to expand CSF-derived CD4+ T cells from the 31 CIS/MS patients was an 
adaptation from a method previously reported (70). Fresh bulk CSF-derived mononuclear cells 
were mixed with 5 x 106 allogeneic irradiated PBMCs and CD4+ T cells were positively selected 
with anti-CD4 magnetic beads. CD4+ fractions were then seeded at 1500 cells per well in 96-
well U-bottom microtiter plates together with 1.5 x 105 allogeneic irradiated PBMC, 1 µg/ml of 
PHA-L and IL-2 supernatant. Medium consisted of RPMI 1640 without Hepes (Pan-Biotech, 
Aidenbach, Germany) supplemented with 2 mM glutamine (Pan-Biotech), 1% (vol/vol) 
nonessential amino acids (Gibco), 1% (vol/vol) sodium pyruvate (Gibco), 50 µg/ml penicillin-
streptomycin (Corning, NY, USA), 0.00001% β-Mercaptoethanol (Gibco) and 5% human serum 
(Blood Bank Basel). Additional IL-2 was added every 4 days. Growing wells were transferred to 
48 well plates and finally to 75 cm3 flask until cells were fully rested (20-25 days). Cells were 
highly expanded in a single round of stimulation.  
An autologous B cell line (BCL) from patient 1154SA was generated by Epstein–Barr virus 
(EBV)-transformation. Bare lymphocyte syndrome (BLS) cells transfected with single HLA class 
II molecules, DR2a (DRA1*01:01, DRB5*01:01), DR2b (DRA1*01:01, DRB1*15:01) and DQw6 
(DQA1*01:02, DQB1*06:02) were kindly provided by Dr. Nepom and Dr. Kwok (University of 
Washington, Seattle). 
T cell stimulation 
TCC responses to single/dual defined peptide mixtures or individual decapeptides were tested 
by seeding in duplicate 2 x 104 T cells and 5 x 104 irradiated BLS cell lines or autologous BCL or 
1 x 105 irradiated PBMC (as indicated) with or without combinatorial peptide mixtures or 
individual decapeptides. 2.5 µg/ml PHA and 10-7 M PMA (Sigma), 1 µg/ml of surface-coated 
anti-CD3 (OKT3, Ortho Biotech Products, Raritan, NJ) and 0.5 µg/ml of soluble anti-CD28 
(Biolegend, San Diego, CA), and a T Cell Activation Kit (anti-CD3, anti-CD28, anti-CD2 beads) 
(Miltenyi Biotec) served as positive controls as indicated. 
The response of PHA-expanded CSF-infiltrating CD4+ T cells to GDP-L-fucose synthase, myelin 
and CEF peptides (Table S2) was tested by seeding in quadruplicate 6 x 104 T cells and 2 x 105 
irradiated autologous PBMCs with or without peptides. For EdU experiments BLS DRB1*15:01 
were used as APCs. T Cell Activation Kit was used as positive control.  
Cytokine measurement 
Cytokines in the supernatant of stimulated and unstimulated TCC21.1 or expanded CSF-
infiltrating T cells were measured after 48 h of culture using the Human T Helper Cytokine Panel 
LEGENDplex bead-based immunoassay (Biolegend), GM-CSF ELISA (BD Biosciences, 
Franklin Lakes, NJ) and IL-3 ELISA (Biolegend) according to the manufacturer´s instructions. 
The amount of each cytokine released by TCC21.1 or expanded CSF-infiltrating T cells to 
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specific or unspecific stimuli was normalized by subtracting the amount of the corresponding 
cytokine released by T cells in absence of stimulus (negative control). For cytokines defining 
functional phenotypes, i.e. IFNγ for Th1, IL-4 for Th2, IL-17A and -F for Th17, IL-9 for Th9 and 
IL-22 for Th22, a threshold for positivity was defined based on published data (33, 71-73) to 
facilitate functional classification of TCC21.1. 
For intracellular cytokine staining, TCC21.1 was analyzed 48 h after stimulation. After 5 h in 
presence of GolgiStop protein transport inhibitor (BD Biosciences), T cells were labeled with 
Live/Dead® Aqua (Invitrogen). Following fixation and permeabilization with Cytofix/Cytoperm 
(BD Biosciences), cells were stained with antibodies against CD4 (APC-Cy7, Biolegend), IFN-γ 
(FITC, Biolegend), IL-4 (PE, BD Bioscience), GM-CSF (APC, Biolegend) and IL-3 (PE, 
Biolegend) in PBS containing saponin and BSA, and analyzed by flow cytometry.  
Proliferative Responses 
Proliferation was measured 72 h after stimulation by 3H-thymidine (Hartmann Analytic, 
Braunschweig, Germany) incorporation in a scintillation counter (Wallac 1450, PerkinElmer, 
Rodgau-Jürgesheim, Germany). The stimulatory index (SI) was calculated as follows: SI = 
Median (replicates cpm peptide) / Median (replicates cpm without peptide). 
Proliferation was also measured using a Click-iTTM EdU Flow Cytometry Assay Kit (APC, 
Molecular Probes, Invitrogen) following manufacturer’s instructions. Cells were stained with the 
following antibodies anti-CD3 (PE-Cy-7, e-Bioscience, San Diego, CA) and anti-TRBV-21 
(FITC, Beckman Coulter, Brea, CA) and analyzed by flow cytometry. 
Surface receptor expression 
Resting TCC21.1 was stained with antibodies against CD4 (PE-Texas Red, Thermo Fischer, 
Waltham, MA), TRBV21 (FITC, Beckman Coulter), CD28 (PE-Cy7, BioLegend), CCR4 (APC, 
BioLegend), CCR6 (BV785, BioLegend) and CRTh2 (PE, BioLegend) and analyzed by flow 
cytometry. 
Flow Cytometric Analysis 
Sample acquisition was conducted using a LSR Fortessa Flow Cytometer (BD Biosciences) 
with Diva software, and data were analyzed with FlowJo (Tree Star, Ashland, OR). 
RT-PCR and Sequencing of TCR Rearrangements 
RNA extraction, reverse transcription and TCRα/β-chain (TRA/BV) sequencing of TCC21.1 and 
TCL-39 was assessed as previously reported (26). TCR gene designations are in accord with 
IMGT nomenclature (ImMunoGeneTics, www.IMGT.org). 
HLA 
GDP-L-fucose synthase as putative autoantigen in MS 	  
	   20	  
Individuals were typed for HLA-class I and II molecules at Histogenetics LLC, NY, USA. 
Isolation of DNA from whole blood with a final concentration of 15 ng/µl was performed with a 
standard DNA isolation protocol using a Triton lysis buffer and Proteinase K treatment. The 
samples were typed for HLA class I (A* and B*) and HLA class II (DRB1*, DRB3*, DRB4*, 
DRB5*, DQA1* and DQB1*) using high-resolution HLA sequence-based typing (SBT). 
The MHC class II binding predictions were made using the IEDB analysis resource Consensus 
tool (74, 75). 
Statistical analysis 
Three-cluster k-means analysis was performed on patient scores to group patients into three 
categories.  Associations between response levels of peptides, patients, and HLA status were 
all performed using Fisher’s Exact Test with Bonferroni-Holm correction applied as appropriate, 
with 5% significance.  
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SUPPLEMENTARY MATERIALS 
Supplementary Figures 
Figure S1. Integration of stimulatory responses from testing dual-defined mixtures into the 
original scoring matrix  
Figure S2. Response of CSF-infiltrating CD4+ T cells 
Figure S3. New CIS/MS patients and phylogeny of bacterial species sharing GDP-L-fucose 
synthase peptides 
Supplementary Tables 
Table S1. Summary of human decapeptides predicted with the biometrical approach, 
synthesized and tested for stimulatory capacity 
Table S2. GDP-L-fucose synthase, myelin and CEF Peptides 
Table S3. Peptides from brain proteins identified by proteomic analysis in brain tissue. 
Table S4. Patient classification and HLA binding 
Table S5. Bacteria selected for GDP-L-fucose synthase comparison 
Table S6. Sequence homology between human and bacterial GDP-L-fucose synthase peptides 
Table S7. Demographical and clinical characteristics of MS patients and non-MS controls 
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FIGURE LEGENDS 
Figure 1. Single and dual-defined decapeptide positional scanning mixtures in 
combination with biometric analysis to identify the specifity of TCC21.1. A GM-CSF 
production by TCC21.1 in response to 20 combinatorial peptide mixtures with AAs defined at 
position 5 and presented by BLS cells expressing only DRB1*15:01, DRB5*01:01 or 
DQB1*06:02 class II molecules. X-axes, single-letter AA code; Y-axes, cytokine production. B. 
GM-CSF (black histograms) and IL-10 (white histograms) production by TCC21.1 in response to 
a complete decapeptide positional scanning library (200 mixtures) presented by BLS cells 
expressing only DRB1*15:01. C. Score matrix designed with the log10 median of GM-CSF 
production of three independent experiments. Dark grey cells correspond to values equal or 
higher than 2 and light grey cells to values between 1.5 and 2. Bold borders show mixtures 
selected for dual defined mixtures, continuous borders based on GM-CSF results and dotted 
borders on IL-10 results. D. GM-CSF production by TCC21.1 in response to the 50 peptides 
with highest scores predicted using the GM-CSF based score matrix. E. GM-CSF production by 
TCC21.1 in response to 22 dual-defined mixtures. In green, mixtures with defined AAs of the 
TCR motif in frame 1 and in blue in frame 2. Stimulatory responses of mixtures shown with 
darker colors (Frame 1/2-HM) were integrated into the original matrix using the harmonic mean 
model. F. TCR motif and dual-defined mixture activity values selected based on the harmonic 
mean model and incorporated into the original matrix, Frame 1-HM in green and Frame 2-HM in 
blue. G. GM-CSF production by TCC21.1 in response to the 50 peptides with higher scores 
predicted using harmonic boost frame 1 and 2 score matrices. Complete decapeptide library, 
dual defined mixtures and individual decapeptides were presented by BLS cells expressing 
DRB1*15:01. Mixtures were tested at 200 µg/ml and individual decapeptides at 5 µg/ml. 
Histograms show mean ± standard error mean (SEM) and dot plots mean of three independent 
experiments. Cytokine released is always expressed as pg/ml released by TCC21.1 in response 
to stimuli minus pg/ml released in absence of stimulus (negative control). 
 
Figure 2. Characterization of TCC21.1 response to GDP-L-fucose synthase peptides. A. 
GM-CSF production by TCC21.1 in response to eleven decapeptides overlapping by nine AA 
and tested at 0.5 and 5 µg/ml. B-C. GM-CSF dose response of TCC21.1 to GDP-L-fucose 
synthase peptide (96-105) presented by BLS cells expressing DRA*01:01/DRB1*15:01, 
DRA*01:01/DRB5*01:01 or DQA1*01:02/DQB1*06:02 class II molecules. D. GM-CSF 
production by TCC21.1 in response to 13 alanine scan peptides presented by BLS cells 
expressing DRA*01:01/DRB1*15:01. Alanine substitution is shown in grey. E-F. Proliferative 
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responses (white histograms) and production of cytokines (black histograms) by TCC21.1 in 
response to GDP-L-fucose synthase peptides presented by autologous PBMCs/BCL and 
unspecific stimulus. F. Proliferative response (white histograms) and GM-CSF and IL-3 
production (black histograms) by TCC21.1 and other TCCs with different functional phenotype 
in response to the corresponding specific peptides presented by autologous PBMCs, for 
TCC21.1 also autologous BCL, and to unspecific stimuli. Cytokine released is always expressed 
as pg/ml released by TCC21.1 in response to stimuli minus pg/ml released in absence of 
stimulus (negative control). All results show the mean ± SEM. Dotted lines show a putative 
threshold for positivity: SI=2 in proliferation histograms and the amount of IFNγ, IL-4, IL-17, IL-9 
and IL-22 released by T cells with Th1, Th2, Th17, Th9 Th22 functional phenotype respectively. 
G. Representative flow cytometry analysis of intracellular IL-4, IFN-γ, GM-CSF and IL-3 
production by TCC21.1 in response to GDP-L-fucose synthase peptide (96-105) and 
PMA/Ionomycin. Numbers represent the percentage of positive cells. H. Histograms 
representing the mean fluorescence intensity of CD28, CCR4, CCR6 and CRTh2 on the surface 
of resting TCC21.1 (black lines) in comparison to the isotype control staining (gray shaded). 
 
Figure 3. Recognition of GDP-L-fucose synthase peptides by TCC21.1 and CSF-
infiltrating CD4+ T cells from patient 1154SA. A. Proliferative responses expressed as SI of 
TCC21.1 and CSF-infiltrating CD4+ T cells after short- and long PHA expansion, to GDP-L-
fucose synthase-, myelin- and CEF peptides presented by autologous PBMCs as well as to 
control beads. TCC21.1 graph shows the mean SI ± SEM, while in the CSF graphs each dot 
represents one well. Positive peptides are shown in black. B. Proliferation of long expanded 
CSF-infiltrating CD4+ T to GDP-L-fucose synthase peptide (91-105), CEF pool and PHA using 
as APCs BLS DRA*01:01/DRB1*15:01 and assessed by EdU incorporation. Numbers represent 
the percentage of EdU-positive cells. C. Proliferative responses expressed as stimulation 
indexes (SI) of positive wells to GDP-L-fucose synthase peptide (191-205) for generation of 
TCL-39. D. TCRBV sequencing of TCCs present in TCL-39. E. Production of cytokines of long 
expanded CSF-infiltrating CD4+ T to GDP-L-fucose synthase peptides 91-105 and 191-205 
presented by autologous PBMCs as well as to control beads. Cytokine released is expressed as 
pg/ml released by stimulated cells minus pg/ml released in absence of stimulus (negative 
control). Results show the mean ± SEM. 
 
Figure 4. Recognition of GDP-L-fucose synthase peptides by CSF-infiltrating CD4+ T cells 
from moderate and high responder CIS/MS patients. A. Proliferative responses expressed 
as stimulation indexes (SI) of CSF-infiltrating CD4+ T cells (single round of PHA expansion) to 
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GDP-L-fucose synthase and CEF peptides presented by autologous PBMCs as well as to 
control beads. Each dot represents one well, and median SIs are shown as solid lines. Positive 
peptides (black dots and red line) are peptides with median of all SIs > 1.455 (dotted red line). 
All peptides have been tested in four wells, except for peptides 156-170 and/or 161-175 in 
748UR, 1129RE, 1005ME, 1173DI, 718MA and 776JE, which were tested also for bacterial 
peptides by seeding 8 wells. B. Number of CIS/MS patients with CSF-infiltrating CD4+ T cells 
that responded to GDP-L-fucose synthase peptides. Immunodominant peptides that were 
positive in at least three patients are shown in red. Solid red are high responder and light red 
moderate responder patients. C. Production of cytokines of CSF-infiltrating CD4+ T cells from 
three patients to GDP-L-fucose synthase immunodominant peptides presented by autologous 
PBMCs. 
 
Figure 5. Recognition of myelin peptides by CSF-infiltrating CD4+ T cells from CIS/MS 
patients. A. Proliferative responses expressed as stimulation indexes (SI) of CSF-infiltrating 
CD4+ T cells (single round of PHA expansion) to myelin peptides presented by autologous 
PBMCs. Each dot represents one well, and median SIs are shown as solid lines. Positive 
peptides (black wells and red line) are peptides with median of all SIs > 1.455 (dotted red line). 
B. Checkerboard graph illustrating GDP-L-fucose synthase immunodominant (red) and myelin 
(blue) peptides recognized by each CIS/MS patient. Solid colors are GDP-L-fucose synthase 
and myelin peptides showing significant correlation between them. P values for Fisher’s exact 
tests with Bonferroni-Holm correction are shown. 
 
Figure 6. Recognition of bacterial GDP-L-fucose synthase peptides by CSF-infiltrating 
CD4+ T cells from CIS/MS patients. Proliferative responses expressed as stimulation indexes 
(SI) of CSF-infiltrating CD4+ T cells (single round of PHA expansion) to eight bacterial GDP-L-
fucose synthase peptides, sharing with the human homologous peptide at least six of the 15 
amino acids (blue), presented by autologous PBMCs. Each dot represents one well and median 
SIs are shown as solid lines. Positive peptides (black wells and red line) are peptides with 
median of all SIs > 2 (dotted red line). 
Table 1. GDP-L-fucose synthase transcripts and peptides identified in brain tissue. 
  Transcriptome    Proteome (PSM3) Distinct Protein 
 Gene RPKM1 UniProt   MS Non-MS  peptides coverage 
Protein ID LI2 LII LIII ID Peptide sequence Residues WM GM WM GM Total # % 
GDP-L-fucose synthase TSTA3 2.17 2.02 2.67 Q13630 ILVTGGSGLVGK 10 - 21 12 12 12 12 48 17 56.0 
      VVADGAGLPGEDWVFVSSK 26 - 44 12 12 12 12 48   
      DADLTDTAQTR 45 - 55 12 12 12 12 48   
      VQPTHVIHLAAMVGGLFR 61 - 78 - 9 9 9 27   
      YNLDFWR 82 - 88 12 12 12 12 48   
      YNLDFWRK 82 - 89 - - - 1 1   
      NVHMNDNVLHSAFEVGAR 90 - 107 - 13 13 13 39   
      NVHMNDNVLHSAFEVGARK 90 - 108 - - - 3 3   
      VVSCLSTCIFPDK 109 - 121 - - - 3 3   
       MIDVQNR 149 - 155 - 2 - 2 4   
      RMIDVQNR 148 - 155 - - 2 2 4   
      SSGSALTVWGTGNPR 200 - 214 3 - - - 3   
      SSGSALTVWGTGNPRR 200 - 215 - - 1 - 1   
      TTYPIDETMIHNGPPHNSNFGYSYAK 222 - 247 - - 3 - 3   
      EYNEVEPIILSVGEEDEVSIK 233 - 253 - 3 - - 3   
        TYLPDFR 291 - 297 12 12 12 12 48   
      LRTYLPDFR 289 - 297 - - - 2 2   
        63 87 88 95 333   
               
Myelin basic protein MBP 37.20 28.97 59.21 P02686   993 871 985 865 3714 80 79.6 








216 199 222 216 853 28 
 
49.8 
Myelin-associated glycoprotein MAG 16.29 10.83 26.84 P20916   243 232 221 243 939 34 36.9 
Myelin-associated 
oligodendrocyte basic protein 
 
























1168 985 1157 1060 4370 112 
 
96.4 
1 RPKM, reads per kilobase of exon model per million mapped reads. 2 LI and LIII, active lesions in which TCC21.1 was clonally expanded. LII, inactive lesion in which TCC21.1 
was not idenfied. 3 PSM, peptide spectrum matches. Proteome data correspond to white matter (WM) and grey matter (GM) from multiple sclerosis patients (MS, n=15) and non-
MS controls (Non-MS, n=9). In bold are GDP-L-fucose synthase values. 
Table 2. Demographical and clinical characteristics of CIS/MS patients and HLA-DR –DQ typing.  
 Patient    IgG CSF HLA 
 ID Disease Sex Age Index # cells/uL DRB1* DRB1* DRB3* DRB3* DRB4* DRB4* DRB5* DRB5* DQA1* DQA1* DQB1* DQB1* 
UNRESPONDERS 
 66JO RRMS F 38 2.89 8 15:01 15:01     01:01 01:01 01:02 01:02 06:02 06:02 
 103HR CIS M 37 0.68 9 15:01 15:01     01:01 01:01 01:02 01:02 06:02 06:02 
 0204AM RRMS F 38 1.04 8 15:01 15:01     01:01 01:01 01:02 01:02 06:02 06:02 
 0247PE SPMS F 39 1.5 3 15:01 07:01   01:03  01:01  01:02 02:01 06:02 03:03 
 0381MA SPMS F 45 0.5 3 15:01 04:01   01:01  01:01  01:02 03:XX 06:02 03:02 
 0702AN RRMS M 45 0.73 5 15:01 01:03     01:01  01:02 05:01 03:01 06:02 
 0740RA CIS F 35 0.5 3 04:01 07:01   01:01 01:01   02:01 03:01 02:01 03:01 
 0936MA RRMS F 31 0.66 2 15:01 15:01     01:01 01:01 01:02 01:02 06:02 06:02 
 0973JO RRMS M 22 0.51 18 15:01 04:02   01:01  01:01  01:02 03:01 03:02 06:02 
 1125PA RRMS M 41 0.63 6 04:02 14:54  02:02 01:01    01:01 03:01 03:02 05:03 
 1292DI RRMS F 27 1.28 10 15:01 16:01     01:01 02:02 01:02 01:02 05:02 06:02 
 1300EV RRMS F 37 0.57 2 03:01 08:01  02:02     04:01 05:01 02:01 04:02 
 0897UR RRMS F 34 1.97 7 15:01 08:01     01:01  01:02 04:01 04:02 06:02 
 0127RO CIS M 30 1.38 27 15:01 08:01     01:01  01:02 04:01 04:02 06:02 
 1290JA SPMS M 27 0.5 8 15:01 04:04   01:01  01:01  03:02 06:02 01:02 03:XX 
 0800TH RRMS M 22 0.52 7 15:01 11:04  02:02   01:01  01:02 05:01 03:01 06:02 
 0830OL CIS F 36 0.56 4 15:01 11:01  02:02   01:01  01:02 05:01 03:01 06:02 
 0818MA RRMS M 37 0.67 3 03:01 04:07 01:01  01:01    03:01 05:01 02:01 03:01 
 1206CO RRMS F 37 1.37 5 15:01 04:01   01:01  01:01  01:02 03:01 03:02 06:02 
MODERATE RESPONDERS 
 0780UR RRMS M 27 1.19 8 15:01 09:01   01:01  01:01  01:02 03:01 03:03 06:02 
 0866JE RRMS F 30 1.14 10 11:01 13:01 01:01 02:02     01:03 05:01 03:01 06:03 
 0748UR RRMS M 53 1.49 7 15:01 15:01     01:01 01:01 01:02 01:02 06:02 06:02 
 1346JU RRMS F 21 1.09 12 07:01 13:01 01:01  01:01    01:03 02:01 02:01 06:03 
 1081SA CIS F 49 0.71 23 01:01 08:03       01:01 06:01 03:01 05:01 
 0817JD RRMS M 28 0.53 6 15:01 03:01 01:01     01:01 01:02 05:01 02:01 06:02 
HIGH RESPONDERS 
 1129RE RRMS M 32 0.92 3 07:01 11:03  02:02 01:03    02:01 05:01 03:01 03:03 
 1005ME CIS F 33 0.76 4 15:03 03:01  02:02   01:01  01:02 05:01 02:01 06:02 
 1173DI RRMS M 32 0.51 14 04:04 11:04  02:02 01:01    03:01 05:01 03:02 03:01 
 0718MA RRMS F 36 0.54 1 15:01 03:01  02:02   01:01  05:01 05:01 02:01 03:01 
 0816DA CIS F 52 1.14 12 15:01 13:01  02:02   01:01  01:03 01:02 06:02 06:03 
 0776JE CIS F 28 0.7 6 03:01 08:03  02:02     05:01 06:01 02:01 03:01 	  
Individual activity insufficient 
to explain mixture activity 
Individual activity now sufficient 
to explain mixture activity 
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Figure 1 
F- Motif with flanking residues  
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GM-­‐CSF	  (pg/ml)	  
E- Synthesis and test of dual-defined mixtures 
1 2 3 4 5 6 7 8 9 10
Acetyl I K X X X X X X X X NH2
Acetyl X K L X X X X X X X NH2
Acetyl X R L X X X X X X X NH2
Acetyl X X K L X X X X X X NH2
Acetyl X X L H X X X X X X NH2
Acetyl X X X H S X X X X X NH2
Acetyl X X X L H X X X X X NH2
Acetyl X X X X H S X X X X NH2
Acetyl X X X X S S X X X X NH2
Acetyl X X X X X X F E X X NH2
Acetyl X X X X X X X E V X NH2
Acetyl X X X X X X X F E X NH2
Acetyl X X X X X X X X E V NH2
Acetyl X X X H X X X E X X NH2
Acetyl X X X K X X X F X X NH2
Acetyl X X X L X X X F X X NH2
Acetyl X X X H X X X X V X NH2
Acetyl X X X L X X X X E X NH2
Acetyl X X X X H X X F X X NH2
Acetyl X X X X S X X E X X NH2
Acetyl X X X X H X X X E X NH2
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Figure S1. Integration of stimulatory response from testing dual-defined mixtures into the original scoring matrix using the harmonic mean model. 
In order to integrate the responses from testing dual-defined mixtures into the original scoring matrix using the harmonic mean model, we first retested single 
defined mixtures along with the dual defined mixtures and used them to normalize all activity values to a single scale using linear regression.  Then, all GM-
CSF (pg/ml) values for all single defined and dual defined at all doses were converted to Approximate EC50 values using the formula:  
Approximate EC50= [Tested Concentration] * (MaximumGMCSF / GMCSF-1) 
Next, the harmonic mean was taken of each pair of single-defined Approximate EC50 that had a corresponding dual defined mixture, and the value was 
compared to that of the dual defined mixture. For example, the Approximate EC50 of the dual defined mixture with L defined in the fourth position and H 
defined in the fifth position was compared to the harmonic mean of the  Approximate EC50 values of the two corresponding single defined mixtures: the first 
with L defined in the fourth position, and the second with H defined in the fifth position.  The harmonic mean model dictates that the dual defined mixture 
contains more active individual peptides than either of the single defined mixtures only if its activity is greater than the harmonic mean of the two single 
defined mixtures27 (i.e., when the fold over the harmonic mean is greater than one).  In total, five dual defined mixtures in Frame 1 (Green) and four in Frame 
2 (Blue) exhibited this property (the dual-defined mixtures in darker colors and bolded Fold Over Harmonic Mean).  All Approximate EC50 values were 
converted back to GM-CSF (pg/ml) values at 200 ug/ml, and then those amino acids and position corresponding to the five dual defined mixtures in Frame 1 
had added to them the log base 10 of the highest activity value among the dual defined mixtures with that position defined (Fig. S1, bold values in Log10 
median table, as opposed to the lower numerical values in grey).  For example, both the dual defined mixture with F defined in position seven and E in 
position eight, and the dual defined mixture with E in position eight and V in position nine, had activity values greater than their associated harmonic means.  
The value added to E in the eighth position of the matrix was the activity value for the dual defined mixture with F defined in position seven and E in position 
eight, because it was the higher of the two (2.5 versus 2.4).  Frame 2 was treated the same way, creating the two “updated” matrices shown that were then 
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Figure S2. Response of CSF-infiltrating CD4+ T cells. A. Response of CSF-infiltrating CD4+ T cells from nonresponder CIS/
MS patients to GDP-L-fucose synthase peptides. Proliferative responses expressed as stimulation indexes (SI) of CSF-infiltrating 
CD4+ T cells (single round of PHA expansion) to GDP-L-fucose synthase and CEF peptides presented by autologous PBMCs as 
well as to control beads. Each dot represents one replicate well and median SIs are shown as solid lines. Positive peptides 
(black dots and red line) are peptides with median of  SIs > 1.455 (dotted red line). All peptides have been tested in four replicate 
wells. B. Graphs comparing the proliferative responses of CSF-infiltrating CD4+ T cells to CEF peptides, control beads and only 
medium (negative control) for the different responder groups. In the CEF peptide pool and control beads graphs, each dot 
represents the median SIs of four wells for one individual patient. In the negative control graph, each dot represents the SI of one 
individual well and it has been calculated as: cpm in one individual well without peptide / Median (all replicates cpm without 









































Figure S3. New patients and phylogeny of bacterial species sharing GDP-L-fucose synthase peptides. A. 
Proliferative responses expressed as stimulation indexes (SI) of CSF-infiltrating CD4+ T cells (single round of PHA 
expansion) to GDP-L-fucose synthase and CEF peptides presented by autologous PBMCs as well as to control beads. 
Each dot represents one well, and median SIs are shown as solid lines. Positive peptides (black dots and red line) are 
peptides with median of all SIs > 1.455 (dotted red line). B. HLA class II typing. C. Phylogeny of bacterial species 
sharing GDP-L-fucose synthase peptides. In black are represented stimulatory peptides in four patients, in dark grey in 
one to three patients and in light grey non stimulatory. Genera common in gut microbiota are shown in red.  
Table	  S1.	  Summary	  of	  human	  decapeptides	  predicted	  with	  the	  biometrical	  approached,	  synthesized	  and	  tested	  for	  stimulatory	  capacity
PEPTIDES	  FROM	  HUMAN	  PROTEINS Peptides	  tested	  at	  5	  mg/ml
Matrix Uniprot	  Database Rank Score PercentMax Matrix Uniprot	  Database Rank Database Rank Score PercentMax 10mer Protein Mean	  GM-­‐CSF	  (pg/ml)
Original Human 1 19.79 86.9% HM	  Boost	  Frame	  2 Human 4 Brain	  Lesions 4 27.14 81.0% RKKLHKFEET |Q96PE3|INP4A_HUMAN	  Type	  I	  inositol	  3,4-­‐bisphosphate	  4-­‐phosphatase	  OS=Homo	  sapiens	  GN=INPP4A	  PE=1	  SV=1 3
Original Human 2 19.27 84.6% HM	  Boost	  Frame	  2 Human 5 Brain	  Lesions 5 26.96 80.4% LKKLHDFEEQ |Q9BX84|TRPM6_HUMAN	  Transient	  receptor	  potential	  cation	  channel	  subfamily	  M	  member	  6	  OS=Homo	  sapiens	  GN=TRPM6	  PE=1	  SV=2 9
Original Human 3 19.21 84.3% HM	  Boost	  Frame	  2 Human 7 Brain	  Lesions 7 26.90 80.3% QKKLHDFEEQ |Q96QT4|TRPM7_HUMAN	  Transient	  receptor	  potential	  cation	  channel	  subfamily	  M	  member	  7	  OS=Homo	  sapiens	  GN=TRPM7	  PE=1	  SV=1 9
Original Human 4 18.99 83.4% HM	  Boost	  Frame	  2 Human 8 Brain	  Lesions 8 26.90 80.3% QKKLSSGEEK |Q15858|SCN9A_HUMAN	  Sodium	  channel	  protein	  type	  9	  subunit	  alpha	  OS=Homo	  sapiens	  GN=SCN9A	  PE=1	  SV=3 4
Original Human 5 18.89 82.9% HM	  Boost	  Frame	  1 Human 45 26.35 72.1% RKLLHRFETE |O15327|INP4B_HUMAN	  Type	  II	  inositol	  3,4-­‐bisphosphate	  4-­‐phosphatase	  OS=Homo	  sapiens	  GN=INPP4B	  PE=2	  SV=4 14
Original Human 6 18.78 82.4% HM	  Boost	  Frame	  2 Human 1 Brain	  Lesions 1 28.47 84.9% RRKLHSFYEV |Q5VST9|OBSCN_HUMAN	  Obscurin	  OS=Homo	  sapiens	  GN=OBSCN	  PE=1	  SV=3 13
Original Human 7 18.71 82.1% KKKKVAGEEE |I3L1I4|I3L1I4_HUMAN	  Chromodomain-­‐helicase-­‐DNA-­‐binding	  protein	  3	  (Fragment)	  OS=Homo	  sapiens	  GN=CHD3	  PE=4	  SV=1 0
Original Human 8 18.54 81.4% LKKVHDFEEQ |Q9HCF6|TRPM3_HUMAN	  Transient	  receptor	  potential	  cation	  channel	  subfamily	  M	  member	  3	  OS=Homo	  sapiens	  GN=TRPM3	  PE=2	  SV=4 49
Original Human 9 18.19 79.9% KKLLLHVEEV |Q8N8V2|GBP7_HUMAN	  Guanylate-­‐binding	  protein	  7	  OS=Homo	  sapiens	  GN=GBP7	  PE=2	  SV=2 64
Original Human 10 18.18 79.8% HM	  Boost	  Frame	  1 Human 4 Brain	  Lesions 4 28.28 77.3% QKKHSGFEDE |P10645|CMGA_HUMAN	  Chromogranin-­‐A	  OS=Homo	  sapiens	  GN=CHGA	  PE=1	  SV=7 9
Original Human 11 18.12 79.5% LKKKSHMEEK |Q49MG5|MAP9_HUMAN	  Microtubule-­‐associated	  protein	  9	  OS=Homo	  sapiens	  GN=MAP9	  PE=1	  SV=3 6
Original Human 12 18.01 79.1% KKKKSALFEV |Q9GZU0|CF062_HUMAN	  Uncharacterized	  protein	  C6orf62	  OS=Homo	  sapiens	  GN=C6orf62	  PE=2	  SV=1 4
Original Human 13 18.01 79.1% RKKKSALFEV |Q9GZU0-­‐2|CF062_HUMAN	  Isoform	  2	  of	  Uncharacterized	  protein	  C6orf62	  OS=Homo	  sapiens	  GN=C6orf62 0
Original Human 14 18.00 79.0% IWKKLSFEEV |Q96JI7|SPTCS_HUMAN	  Spatacsin	  OS=Homo	  sapiens	  GN=SPG11	  PE=1	  SV=3 8
Original Human 15 18.00 79.0% HM	  Boost	  Frame	  2 Human 13 Brain	  Lesions 13 25.87 77.2% LKRLHEFEEQ |Q7Z4N2|TRPM1_HUMAN	  Transient	  receptor	  potential	  cation	  channel	  subfamily	  M	  member	  1	  OS=Homo	  sapiens	  GN=TRPM1	  PE=1	  SV=2 6
Original Human 16 17.97 78.9% HM	  Boost	  Frame	  1 Human 3 Brain	  Lesions 3 28.40 77.7% LKLHSRFYEL |O75838|CIB2_HUMAN	  Calcium	  and	  integrin-­‐binding	  family	  member	  2	  OS=Homo	  sapiens	  GN=CIB2	  PE=1	  SV=1 55
Original Human 17 17.89 78.5% QKKLHKFELA |O15514|RPB4_HUMAN	  DNA-­‐directed	  RNA	  polymerase	  II	  subunit	  RPB4	  OS=Homo	  sapiens	  GN=POLR2D	  PE=1	  SV=1 27
Original Human 18 17.74 77.9% LGLHHHGEEA |Q9BWH6|RPAP1_HUMAN	  RNA	  polymerase	  II-­‐associated	  protein	  1	  OS=Homo	  sapiens	  GN=RPAP1	  PE=1	  SV=3 7
Original Human 19 17.74 77.9% HM	  Boost	  Frame	  1 Human 12 Brain	  Lesions 11 27.63 75.6% RRLHLHFERV |Q6UXD5|SE6L2_HUMAN	  Seizure	  6-­‐like	  protein	  2	  OS=Homo	  sapiens	  GN=SEZ6L2	  PE=1	  SV=2 3
Original Human 20 17.72 77.8% HM	  Boost	  Frame	  2 Human 3 Brain	  Lesions 3 27.26 81.3% RRLLSSGFEE |O60518|RNBP6_HUMAN	  Ran-­‐binding	  protein	  6	  OS=Homo	  sapiens	  GN=RANBP6	  PE=1	  SV=2 3
Original Human 21 17.70 77.7% KKKKHSTEGV |P51003|PAPOA_HUMAN	  Poly(A)	  polymerase	  alpha	  OS=Homo	  sapiens	  GN=PAPOLA	  PE=1	  SV=4 6
Original Human 22 17.66 77.5% HM	  Boost	  Frame	  1 Human 9 Brain	  Lesions 8 27.89 76.3% QRLHLHFEKV |Q53EL9|SEZ6_HUMAN	  Seizure	  protein	  6	  homolog	  OS=Homo	  sapiens	  GN=SEZ6	  PE=1	  SV=2 5
Original Human 23 17.58 77.2% SKKHHRGEVC |Q8N7U6|EFHB_HUMAN	  EF-­‐hand	  domain-­‐containing	  family	  member	  B	  OS=Homo	  sapiens	  GN=EFHB	  PE=2	  SV=4 0
Original Human 24 17.56 77.1% HM	  Boost	  Frame	  2 Human 2 Brain	  Lesions 2 27.46 81.9% RKLLSSGFEI |Q8N8A2|ANR44_HUMAN	  Serine/threonine-­‐protein	  phosphatase	  6	  regulatory	  ankyrin	  repeat	  subunit	  B	  OS=Homo	  sapiens	  GN=ANKRD44	  PE=1	  SV=3 5
Original Human 25 17.54 77.0% IKKKHLFENS |Q8NBU5|ATAD1_HUMAN	  ATPase	  family	  AAA	  domain-­‐containing	  protein	  1	  OS=Homo	  sapiens	  GN=ATAD1	  PE=1	  SV=1 0
Original Human 26 17.53 77.0% HM	  Boost	  Frame	  2 Human 31 Brain	  Lesions 28 24.72 73.7% QKKLHHFFIG |Q8IWB1|IPRI_HUMAN	  Inositol	  1,4,5-­‐trisphosphate	  receptor-­‐interacting	  protein	  OS=Homo	  sapiens	  GN=ITPRIP	  PE=1	  SV=1 0
Original Human 27 17.52 76.9% AKLHHGFGEA |Q9P2P6|STAR9_HUMAN	  StAR-­‐related	  lipid	  transfer	  protein	  9	  OS=Homo	  sapiens	  GN=STARD9	  PE=1	  SV=3 1
Original Human 28 17.46 76.6% LKHVSHGEEL |Q9NZ53|PDXL2_HUMAN	  Podocalyxin-­‐like	  protein	  2	  OS=Homo	  sapiens	  GN=PODXL2	  PE=1	  SV=1 0
Original Human 29 17.46 76.6% QKKIHKFEEA |Q8N8E3|CE112_HUMAN	  Centrosomal	  protein	  of	  112	  kDa	  OS=Homo	  sapiens	  GN=CEP112	  PE=1	  SV=2 0
Original Human 30 17.45 76.6% LHKKHYFEVL |Q96JI7|SPTCS_HUMAN	  Spatacsin	  OS=Homo	  sapiens	  GN=SPG11	  PE=1	  SV=3 1
Original Human 31 17.42 76.5% LKKHLSGEEH |Q96EU6|RRP36_HUMAN	  Ribosomal	  RNA	  processing	  protein	  36	  homolog	  OS=Homo	  sapiens	  GN=RRP36	  PE=1	  SV=1 24
Original Human 32 17.40 76.4% HM	  Boost	  Frame	  1 Human 8 Brain	  Lesions 7 27.99 76.5% QKLHLHFERL |Q9BYH1|SE6L1_HUMAN	  Seizure	  6-­‐like	  protein	  OS=Homo	  sapiens	  GN=SEZ6L	  PE=1	  SV=1 10
Original Human 33 17.37 76.3% HM	  Boost	  Frame	  1 Human 24 Brain	  Lesions 18 27.05 74.0% RKLKASFEVS |Q8TDX9|PK1L1_HUMAN	  Polycystic	  kidney	  disease	  protein	  1-­‐like	  1	  OS=Homo	  sapiens	  GN=PKD1L1	  PE=1	  SV=1 338
Original Human 34 17.35 76.2% HM	  Boost	  Frame	  2 Human 25 25.03 74.7% FSKLHTFEEV |Q96JB1|DYH8_HUMAN	  Dynein	  heavy	  chain	  8,	  axonemal	  OS=Homo	  sapiens	  GN=DNAH8	  PE=1	  SV=2 0
Original Human 35 17.32 76.0% RKKLSLDEES |O60296|TRAK2_HUMAN	  Trafficking	  kinesin-­‐binding	  protein	  2	  OS=Homo	  sapiens	  GN=TRAK2	  PE=1	  SV=2 0
Original Human 36 17.31 76.0% HM	  Boost	  Frame	  1 Human 17 27.23 74.5% EKKVSSFEVF |Q9UHG0|DCDC2_HUMAN	  Doublecortin	  domain-­‐containing	  protein	  2	  OS=Homo	  sapiens	  GN=DCDC2	  PE=1	  SV=2 0
Original Human 37 17.24 75.7% HM	  Boost	  Frame	  1 Human 29 Brain	  Lesions 22 26.98 73.8% RKLLSDFPVV |Q4LDE5|SVEP1_HUMAN	  Sushi,	  von	  Willebrand	  factor	  type	  A,	  EGF	  and	  pentraxin	  domain-­‐containing	  protein	  1	  OS=Homo	  sapiens	  GN=SVEP1	  PE=1	  SV=3 7
Original Human 38 17.23 75.6% MKKKSLGEVL |O94827|PKHG5_HUMAN	  Pleckstrin	  homology	  domain-­‐containing	  family	  G	  member	  5	  OS=Homo	  sapiens	  GN=PLEKHG5	  PE=1	  SV=3 124
Original Human 39 17.23 75.6% RKKLVEAEEL |O14578|CTRO_HUMAN	  Citron	  Rho-­‐interacting	  kinase	  OS=Homo	  sapiens	  GN=CIT	  PE=1	  SV=2 0
Original Human 40 17.22 75.6% RHKKSHTEEK |Q03923|ZNF85_HUMAN	  Zinc	  finger	  protein	  85	  OS=Homo	  sapiens	  GN=ZNF85	  PE=2	  SV=3 20
Original Human 41 17.20 75.5% IRKLSSGETV |Q70EL2|UBP45_HUMAN	  Ubiquitin	  carboxyl-­‐terminal	  hydrolase	  45	  OS=Homo	  sapiens	  GN=USP45	  PE=1	  SV=3 7
Original Human 42 17.20 75.5% KEKHHHFTEE |Q6ZWH5|NEK10_HUMAN	  Serine/threonine-­‐protein	  kinase	  Nek10	  OS=Homo	  sapiens	  GN=NEK10	  PE=2	  SV=3 0
Original Human 43 17.20 75.5% KKRRHSFEHV |Q9NR48|ASH1L_HUMAN	  Histone-­‐lysine	  N-­‐methyltransferase	  ASH1L	  OS=Homo	  sapiens	  GN=ASH1L	  PE=1	  SV=2 0
Original Human 44 17.16 75.3% QKRHDDFEEV |O60229|KALRN_HUMAN	  Kalirin	  OS=Homo	  sapiens	  GN=KALRN	  PE=1	  SV=2 0
Original Human 45 17.16 75.3% QKRHEDFEEV |O75962|TRIO_HUMAN	  Triple	  functional	  domain	  protein	  OS=Homo	  sapiens	  GN=TRIO	  PE=1	  SV=2 0
Original Human 46 17.15 75.3% RKKQAHFEEE |O95544|NADK_HUMAN	  NAD	  kinase	  OS=Homo	  sapiens	  GN=NADK	  PE=1	  SV=1 0
Original Human 47 17.13 75.2% HM	  Boost	  Frame	  2 Human 26 Brain	  Lesions 23 24.91 74.3% QAKLSSFEET |Q5TB80|CE162_HUMAN	  Centrosomal	  protein	  of	  162	  kDa	  OS=Homo	  sapiens	  GN=KIAA1009	  PE=1	  SV=2 0
Original Human 48 17.08 75.0% KKMLIDGEEV |Q6PP77|XKR2_HUMAN	  XK-­‐related	  protein	  2	  OS=Homo	  sapiens	  GN=XKRX	  PE=2	  SV=2 0
Original Human 49 17.07 74.9% KKKLVRSEEN |Q8N157|AHI1_HUMAN	  Jouberin	  OS=Homo	  sapiens	  GN=AHI1	  PE=1	  SV=1 0
Original Human 50 17.05 74.8% KKKQVHFFVN |Q96IY4|CBPB2_HUMAN	  Carboxypeptidase	  B2	  OS=Homo	  sapiens	  GN=CPB2	  PE=1	  SV=2 0
HM	  Boost	  Frame	  1 Human 1 Brain	  Lesions 1 31.42 85.9% NVLHSAFEVG |Q13630|FCL_HUMAN	  GDP-­‐L-­‐fucose	  synthase	  OS=Homo	  sapiens	  GN=TSTA3	  PE=1	  SV=1 12,111
HM	  Boost	  Frame	  1 Human 2 Brain	  Lesions 2 29.53 80.7% RKLHSFYEVK |Q5VST9|OBSCN_HUMAN	  Obscurin	  OS=Homo	  sapiens	  GN=OBSCN	  PE=1	  SV=3 56
Original Human 16 17.97 78.9% HM	  Boost	  Frame	  1 Human 3 Brain	  Lesions 3 28.40 77.7% LKLHSRFYEL |O75838|CIB2_HUMAN	  Calcium	  and	  integrin-­‐binding	  family	  member	  2	  OS=Homo	  sapiens	  GN=CIB2	  PE=1	  SV=1 55
Original Human 10 18.18 79.8% HM	  Boost	  Frame	  1 Human 4 Brain	  Lesions 4 28.28 77.3% QKKHSGFEDE |P10645|CMGA_HUMAN	  Chromogranin-­‐A	  OS=Homo	  sapiens	  GN=CHGA	  PE=1	  SV=7 9
HM	  Boost	  Frame	  1 Human 5 Brain	  Lesions 5 28.22 77.2% LALHSVFEGL |Q9NY26|S39A1_HUMAN	  Zinc	  transporter	  ZIP1	  OS=Homo	  sapiens	  GN=SLC39A1	  PE=1	  SV=1 0
HM	  Boost	  Frame	  1 Human 6 28.22 77.2% RRLHSPPEVE |A8MT33|SYC1L_HUMAN	  Synaptonemal	  complex	  central	  element	  protein	  1-­‐like	  OS=Homo	  sapiens	  GN=SYCE1L	  PE=2	  SV=3 0
HM	  Boost	  Frame	  1 Human 7 Brain	  Lesions 6 28.12 76.9% LSLHRMFEVV |Q8WXF8|DEDD2_HUMAN	  DNA-­‐binding	  death	  effector	  domain-­‐containing	  protein	  2	  OS=Homo	  sapiens	  GN=DEDD2	  PE=1	  SV=1 0
Original Human 32 17.40 76.4% HM	  Boost	  Frame	  1 Human 8 Brain	  Lesions 7 27.99 76.5% QKLHLHFERL |Q9BYH1|SE6L1_HUMAN	  Seizure	  6-­‐like	  protein	  OS=Homo	  sapiens	  GN=SEZ6L	  PE=1	  SV=1 10
Original Human 22 17.66 77.5% HM	  Boost	  Frame	  1 Human 9 Brain	  Lesions 8 27.89 76.3% QRLHLHFEKV |Q53EL9|SEZ6_HUMAN	  Seizure	  protein	  6	  homolog	  OS=Homo	  sapiens	  GN=SEZ6	  PE=1	  SV=2 5
HM	  Boost	  Frame	  1 Human 10 Brain	  Lesions 9 27.86 76.2% LLLHSIFELN |H7C3K9|H7C3K9_HUMAN	  Melanophilin	  (Fragment)	  OS=Homo	  sapiens	  GN=MLPH	  PE=2	  SV=1 0
HM	  Boost	  Frame	  1 Human 11 Brain	  Lesions 10 27.72 75.8% NGLHSHSEVL |Q9HCH5|SYTL2_HUMAN	  Synaptotagmin-­‐like	  protein	  2	  OS=Homo	  sapiens	  GN=SYTL2	  PE=1	  SV=3 0
Original Human 19 17.74 77.9% HM	  Boost	  Frame	  1 Human 12 Brain	  Lesions 11 27.63 75.6% RRLHLHFERV |Q6UXD5|SE6L2_HUMAN	  Seizure	  6-­‐like	  protein	  2	  OS=Homo	  sapiens	  GN=SEZ6L2	  PE=1	  SV=2 3
HM	  Boost	  Frame	  1 Human 13 27.59 75.4% LRLHSPPEVT |Q9NZ20|PA2G3_HUMAN	  Group	  3	  secretory	  phospholipase	  A2	  OS=Homo	  sapiens	  GN=PLA2G3	  PE=1	  SV=2 0
HM	  Boost	  Frame	  1 Human 14 27.55 75.3% SHLHSLFRVL |Q8NGR2|OR1L6_HUMAN	  Olfactory	  receptor	  1L6	  OS=Homo	  sapiens	  GN=OR1L6	  PE=2	  SV=2 0
HM	  Boost	  Frame	  1 Human 15 Brain	  Lesions 12 27.27 74.6% VELHSHSEVP |Q92551|IP6K1_HUMAN	  Inositol	  hexakisphosphate	  kinase	  1	  OS=Homo	  sapiens	  GN=IP6K1	  PE=1	  SV=3 0
HM	  Boost	  Frame	  1 Human 16 27.25 74.5% GHLHSQLEVS |Q6ZTK2|YP015_HUMAN	  Putative	  uncharacterized	  protein	  LOC400499	  OS=Homo	  sapiens	  PE=2	  SV=1 0
Original Human 36 17.31 76.0% HM	  Boost	  Frame	  1 Human 17 27.23 74.5% EKKVSSFEVF |Q9UHG0|DCDC2_HUMAN	  Doublecortin	  domain-­‐containing	  protein	  2	  OS=Homo	  sapiens	  GN=DCDC2	  PE=1	  SV=2 0
HM	  Boost	  Frame	  1 Human 18 27.22 74.4% DGLHSSNEVL |Q5TDP6|LGSN_HUMAN	  Lengsin	  OS=Homo	  sapiens	  GN=LGSN	  PE=1	  SV=1 0
HM	  Boost	  Frame	  1 Human 19 Brain	  Lesions 13 27.19 74.4% LSLHSLFELR |Q6U841|S4A10_HUMAN	  Sodium-­‐driven	  chloride	  bicarbonate	  exchanger	  OS=Homo	  sapiens	  GN=SLC4A10	  PE=2	  SV=1 0
HM	  Boost	  Frame	  1 Human 20 Brain	  Lesions 14 27.17 74.3% FTPHSRFEVL |Q9P2E5|CHPF2_HUMAN	  Chondroitin	  sulfate	  glucuronyltransferase	  OS=Homo	  sapiens	  GN=CHPF2	  PE=2	  SV=2 0
HM	  Boost	  Frame	  1 Human 21 Brain	  Lesions 15 27.15 74.2% IKLPSSFEKW |Q0P6D6|CCD15_HUMAN	  Coiled-­‐coil	  domain-­‐containing	  protein	  15	  OS=Homo	  sapiens	  GN=CCDC15	  PE=2	  SV=2 54
HM	  Boost	  Frame	  1 Human 22 Brain	  Lesions 16 27.08 74.0% VMLLSLFEEE |Q9P2P5|HECW2_HUMAN	  E3	  ubiquitin-­‐protein	  ligase	  HECW2	  OS=Homo	  sapiens	  GN=HECW2	  PE=1	  SV=2 0
HM	  Boost	  Frame	  1 Human 23 Brain	  Lesions 17 27.07 74.0% FALHSLFEAK |Q96PN7|TREF1_HUMAN	  Transcriptional-­‐regulating	  factor	  1	  OS=Homo	  sapiens	  GN=TRERF1	  PE=1	  SV=1 0
Original Human 33 17.37 76.3% HM	  Boost	  Frame	  1 Human 24 Brain	  Lesions 18 27.05 74.0% RKLKASFEVS |Q8TDX9|PK1L1_HUMAN	  Polycystic	  kidney	  disease	  protein	  1-­‐like	  1	  OS=Homo	  sapiens	  GN=PKD1L1	  PE=1	  SV=1 338
HM	  Boost	  Frame	  1 Human 25 Brain	  Lesions 19 27.04 73.9% KALHSDFIVK |P52333|JAK3_HUMAN	  Tyrosine-­‐protein	  kinase	  JAK3	  OS=Homo	  sapiens	  GN=JAK3	  PE=1	  SV=2 0
HM	  Boost	  Frame	  1 Human 26 Brain	  Lesions 20 27.01 73.9% KKLRSSFESS |Q5JTJ3|COA6_HUMAN	  Cytochrome	  c	  oxidase	  assembly	  factor	  6	  homolog	  OS=Homo	  sapiens	  GN=COA6	  PE=1	  SV=1 23
HM	  Boost	  Frame	  1 Human 27 27.00 73.8% LQLHSPFERG |Q8TDY3|ACTT2_HUMAN	  Actin-­‐related	  protein	  T2	  OS=Homo	  sapiens	  GN=ACTRT2	  PE=2	  SV=2 0
HM	  Boost	  Frame	  1 Human 28 Brain	  Lesions 21 26.98 73.8% RKCHSSGEVQ |Q8N5D0|WDTC1_HUMAN	  WD	  and	  tetratricopeptide	  repeats	  protein	  1	  OS=Homo	  sapiens	  GN=WDTC1	  PE=1	  SV=2 4
Original Human 37 17.24 75.7% HM	  Boost	  Frame	  1 Human 29 Brain	  Lesions 22 26.98 73.8% RKLLSDFPVV |Q4LDE5|SVEP1_HUMAN	  Sushi,	  von	  Willebrand	  factor	  type	  A,	  EGF	  and	  pentraxin	  domain-­‐containing	  protein	  1	  OS=Homo	  sapiens	  GN=SVEP1	  PE=1	  SV=3 7
HM	  Boost	  Frame	  1 Human 30 Brain	  Lesions 23 26.95 73.7% KKRHSYFEKP |Q13123|RED_HUMAN	  Protein	  Red	  OS=Homo	  sapiens	  GN=IK	  PE=1	  SV=3 11
HM	  Boost	  Frame	  1 Human 31 26.94 73.7% VHLHSFFAVG |Q86VW1|S22AG_HUMAN	  Solute	  carrier	  family	  22	  member	  16	  OS=Homo	  sapiens	  GN=SLC22A16	  PE=1	  SV=1 0
HM	  Boost	  Frame	  1 Human 32 Brain	  Lesions 24 26.89 73.5% EALLSGFEVI |O60503|ADCY9_HUMAN	  Adenylate	  cyclase	  type	  9	  OS=Homo	  sapiens	  GN=ADCY9	  PE=1	  SV=4 0
HM	  Boost	  Frame	  1 Human 33 Brain	  Lesions 25 26.80 73.3% EKLFSQFEVD |Q9NXB0|MKS1_HUMAN	  Meckel	  syndrome	  type	  1	  protein	  OS=Homo	  sapiens	  GN=MKS1	  PE=1	  SV=2 0
HM	  Boost	  Frame	  1 Human 34 Brain	  Lesions 26 26.75 73.1% GDLKSGFEEV |Q1XH10|SKDA1_HUMAN	  SKI/DACH	  domain-­‐containing	  protein	  1	  OS=Homo	  sapiens	  GN=SKIDA1	  PE=2	  SV=1 0
HM	  Boost	  Frame	  1 Human 35 Brain	  Lesions 27 26.69 73.0% KGLHSKKEVP |Q7KZF4|SND1_HUMAN	  Staphylococcal	  nuclease	  domain-­‐containing	  protein	  1	  OS=Homo	  sapiens	  GN=SND1	  PE=1	  SV=1 0
HM	  Boost	  Frame	  1 Human 36 Brain	  Lesions 28 26.61 72.8% EFLASSFEVS |Q15269|PWP2_HUMAN	  Periodic	  tryptophan	  protein	  2	  homolog	  OS=Homo	  sapiens	  GN=PWP2	  PE=1	  SV=2 0
HM	  Boost	  Frame	  1 Human 37 Brain	  Lesions 29 26.57 72.7% GVLHSKFWVV |Q96BZ4|PLD4_HUMAN	  Phospholipase	  D4	  OS=Homo	  sapiens	  GN=PLD4	  PE=2	  SV=2 0
HM	  Boost	  Frame	  1 Human 38 26.51 72.5% KQLVHHFEVD |F8WAS2|F8WAS2_HUMAN	  Inter-­‐alpha-­‐trypsin	  inhibitor	  heavy	  chain	  H1	  OS=Homo	  sapiens	  GN=ITIH1	  PE=2	  SV=1 0
HM	  Boost	  Frame	  1 Human 39 26.50 72.5% RHLHSVLEEL |A1L168|CT202_HUMAN	  Uncharacterized	  protein	  C20orf202	  OS=Homo	  sapiens	  GN=C20orf202	  PE=2	  SV=2 0
HM	  Boost	  Frame	  1 Human 40 Brain	  Lesions 30 26.45 72.3% RLLSSGFEEV |O60518|RNBP6_HUMAN	  Ran-­‐binding	  protein	  6	  OS=Homo	  sapiens	  GN=RANBP6	  PE=1	  SV=2 24
HM	  Boost	  Frame	  1 Human 41 Brain	  Lesions 31 26.45 72.3% QMLHPIFEEA |Q9BS26|ERP44_HUMAN	  Endoplasmic	  reticulum	  resident	  protein	  44	  OS=Homo	  sapiens	  GN=ERP44	  PE=1	  SV=1 0
HM	  Boost	  Frame	  1 Human 42 Brain	  Lesions 32 26.42 72.2% RRLHSTHEEL |Q03001|DYST_HUMAN	  Dystonin	  OS=Homo	  sapiens	  GN=DST	  PE=1	  SV=4 7
HM	  Boost	  Frame	  1 Human 43 Brain	  Lesions 33 26.40 72.2% RKLHWLFELL |Q14997|PSME4_HUMAN	  Proteasome	  activator	  complex	  subunit	  4	  OS=Homo	  sapiens	  GN=PSME4	  PE=1	  SV=2 116
HM	  Boost	  Frame	  1 Human 44 Brain	  Lesions 34 26.40 72.2% VELHSDMEVT |P04275|VWF_HUMAN	  von	  Willebrand	  factor	  OS=Homo	  sapiens	  GN=VWF	  PE=1	  SV=4 0
Original Human 5 18.89 82.9% HM	  Boost	  Frame	  1 Human 45 26.35 72.1% RKLLHRFETE |O15327|INP4B_HUMAN	  Type	  II	  inositol	  3,4-­‐bisphosphate	  4-­‐phosphatase	  OS=Homo	  sapiens	  GN=INPP4B	  PE=2	  SV=4 14
HM	  Boost	  Frame	  1 Human 46 26.31 71.9% NKLISEFEEE |Q8NE09|RGS22_HUMAN	  Regulator	  of	  G-­‐protein	  signaling	  22	  OS=Homo	  sapiens	  GN=RGS22	  PE=1	  SV=3 357
HM	  Boost	  Frame	  1 Human 47 Brain	  Lesions 35 26.30 71.9% SKLVSNKEVV |Q15751|HERC1_HUMAN	  Probable	  E3	  ubiquitin-­‐protein	  ligase	  HERC1	  OS=Homo	  sapiens	  GN=HERC1	  PE=1	  SV=2 171
HM	  Boost	  Frame	  1 Human 48 Brain	  Lesions 36 26.29 71.9% LLLHSLFPVP |Q9UJ68|MSRA_HUMAN	  Mitochondrial	  peptide	  methionine	  sulfoxide	  reductase	  OS=Homo	  sapiens	  GN=MSRA	  PE=1	  SV=1 0
HM	  Boost	  Frame	  1 Human 49 Brain	  Lesions 37 26.28 71.9% RKLDSVFEER |P14780|MMP9_HUMAN	  Matrix	  metalloproteinase-­‐9	  OS=Homo	  sapiens	  GN=MMP9	  PE=1	  SV=3 0
HM	  Boost	  Frame	  1 Human 50 Brain	  Lesions 38 26.25 71.8% RFKHSSTEVL |A7KAX9|RHG32_HUMAN	  Rho	  GTPase-­‐activating	  protein	  32	  OS=Homo	  sapiens	  GN=ARHGAP32	  PE=1	  SV=1	  EXP=0.271770 0
Brain	  Lesions 39 26.25 71.8% QSVHHGFEVV |O15198|SMAD9_HUMAN	  Mothers	  against	  decapentaplegic	  homolog	  9	  OS=Homo	  sapiens	  GN=SMAD9	  PE=1	  SV=1 0
Brain	  Lesions 40 26.23 71.7% HLLNSGFEVP |A7KAX9|RHG32_HUMAN	  Rho	  GTPase-­‐activating	  protein	  32	  OS=Homo	  sapiens	  GN=ARHGAP32	  PE=1	  SV=1	  EXP=0.271770 0
HM	  Boost	  Frame	  2 Human 1 Brain	  Lesions 1 28.47 84.9% RRKLHSFYEV |Q5VST9|OBSCN_HUMAN	  Obscurin	  OS=Homo	  sapiens	  GN=OBSCN	  PE=1	  SV=3 13
Original Human 24 17.56 77.1% HM	  Boost	  Frame	  2 Human 2 Brain	  Lesions 2 27.46 81.9% RKLLSSGFEI |Q8N8A2|ANR44_HUMAN	  Serine/threonine-­‐protein	  phosphatase	  6	  regulatory	  ankyrin	  repeat	  subunit	  B	  OS=Homo	  sapiens	  GN=ANKRD44	  PE=1	  SV=3 5
Original Human 20 17.72 77.8% HM	  Boost	  Frame	  2 Human 3 Brain	  Lesions 3 27.26 81.3% RRLLSSGFEE |O60518|RNBP6_HUMAN	  Ran-­‐binding	  protein	  6	  OS=Homo	  sapiens	  GN=RANBP6	  PE=1	  SV=2 3
Original Human 1 19.79 86.9% HM	  Boost	  Frame	  2 Human 4 Brain	  Lesions 4 27.14 81.0% RKKLHKFEET |Q96PE3|INP4A_HUMAN	  Type	  I	  inositol	  3,4-­‐bisphosphate	  4-­‐phosphatase	  OS=Homo	  sapiens	  GN=INPP4A	  PE=1	  SV=1 3
Original Human 2 19.27 84.6% HM	  Boost	  Frame	  2 Human 5 Brain	  Lesions 5 26.96 80.4% LKKLHDFEEQ |Q9BX84|TRPM6_HUMAN	  Transient	  receptor	  potential	  cation	  channel	  subfamily	  M	  member	  6	  OS=Homo	  sapiens	  GN=TRPM6	  PE=1	  SV=2 9
HM	  Boost	  Frame	  2 Human 6 Brain	  Lesions 6 26.91 80.3% GLLLHSIFEL |H7C3K9|H7C3K9_HUMAN	  Melanophilin	  (Fragment)	  OS=Homo	  sapiens	  GN=MLPH	  PE=2	  SV=1 0
Original Human 3 19.21 84.3% HM	  Boost	  Frame	  2 Human 7 Brain	  Lesions 7 26.90 80.3% QKKLHDFEEQ |Q96QT4|TRPM7_HUMAN	  Transient	  receptor	  potential	  cation	  channel	  subfamily	  M	  member	  7	  OS=Homo	  sapiens	  GN=TRPM7	  PE=1	  SV=1 9
Original Human 4 18.99 83.4% HM	  Boost	  Frame	  2 Human 8 Brain	  Lesions 8 26.90 80.3% QKKLSSGEEK |Q15858|SCN9A_HUMAN	  Sodium	  channel	  protein	  type	  9	  subunit	  alpha	  OS=Homo	  sapiens	  GN=SCN9A	  PE=1	  SV=3 4
HM	  Boost	  Frame	  2 Human 9 Brain	  Lesions 9 26.85 80.1% RKHLHSGQEA |Q5JTD0|TJAP1_HUMAN	  Tight	  junction-­‐associated	  protein	  1	  OS=Homo	  sapiens	  GN=TJAP1	  PE=1	  SV=1 0
HM	  Boost	  Frame	  2 Human 10 Brain	  Lesions 10 26.60 79.4% QKLVHSLFES |O15067|PUR4_HUMAN	  Phosphoribosylformylglycinamidine	  synthase	  OS=Homo	  sapiens	  GN=PFAS	  PE=1	  SV=4 0
HM	  Boost	  Frame	  2 Human 11 Brain	  Lesions 11 26.51 79.1% CYLLHSFEEF |Q4LDE5|SVEP1_HUMAN	  Sushi,	  von	  Willebrand	  factor	  type	  A,	  EGF	  and	  pentraxin	  domain-­‐containing	  protein	  1	  OS=Homo	  sapiens	  GN=SVEP1	  PE=1	  SV=3 0
HM	  Boost	  Frame	  2 Human 12 Brain	  Lesions 12 25.89 77.2% SKTLHSVEEK |Q8TBZ0|CC110_HUMAN	  Coiled-­‐coil	  domain-­‐containing	  protein	  110	  OS=Homo	  sapiens	  GN=CCDC110	  PE=2	  SV=1 0
Original Human 15 18.00 79.0% HM	  Boost	  Frame	  2 Human 13 Brain	  Lesions 13 25.87 77.2% LKRLHEFEEQ |Q7Z4N2|TRPM1_HUMAN	  Transient	  receptor	  potential	  cation	  channel	  subfamily	  M	  member	  1	  OS=Homo	  sapiens	  GN=TRPM1	  PE=1	  SV=2 6
HM	  Boost	  Frame	  2 Human 14 Brain	  Lesions 14 25.86 77.1% VKELHSAEEG |O60941|DTNB_HUMAN	  Dystrobrevin	  beta	  OS=Homo	  sapiens	  GN=DTNB	  PE=1	  SV=1 0
HM	  Boost	  Frame	  2 Human 15 Brain	  Lesions 15 25.59 76.3% SLLLHSQEEK |Q8IWZ3|ANKH1_HUMAN	  Ankyrin	  repeat	  and	  KH	  domain-­‐containing	  protein	  1	  OS=Homo	  sapiens	  GN=ANKHD1	  PE=1	  SV=1 0
HM	  Boost	  Frame	  2 Human 16 Brain	  Lesions 16 25.55 76.2% AVHLHSGEEL |Q92519|TRIB2_HUMAN	  Tribbles	  homolog	  2	  OS=Homo	  sapiens	  GN=TRIB2	  PE=2	  SV=1 0
HM	  Boost	  Frame	  2 Human 17 Brain	  Lesions 17 25.55 76.2% HTRLHSGEEP |Q6IV72|ZN425_HUMAN	  Zinc	  finger	  protein	  425	  OS=Homo	  sapiens	  GN=ZNF425	  PE=2	  SV=1 0
HM	  Boost	  Frame	  2 Human 18 Brain	  Lesions 18 25.51 76.1% MPLLHAIFEV |O43592|XPOT_HUMAN	  Exportin-­‐T	  OS=Homo	  sapiens	  GN=XPOT	  PE=1	  SV=2 1
HM	  Boost	  Frame	  2 Human 19 Brain	  Lesions 19 25.38 75.7% EKKRHSYFEK |Q13123|RED_HUMAN	  Protein	  Red	  OS=Homo	  sapiens	  GN=IK	  PE=1	  SV=3 0
HM	  Boost	  Frame	  2 Human 20 25.32 75.5% QAKLHSQEED |Q4V328|GRAP1_HUMAN	  GRIP1-­‐associated	  protein	  1	  OS=Homo	  sapiens	  GN=GRIPAP1	  PE=1	  SV=1 0
HM	  Boost	  Frame	  2 Human 21 Brain	  Lesions 20 25.27 75.4% QQKKHSGFED |P10645|CMGA_HUMAN	  Chromogranin-­‐A	  OS=Homo	  sapiens	  GN=CHGA	  PE=1	  SV=7 2
HM	  Boost	  Frame	  2 Human 22 Brain	  Lesions 21 25.12 74.9% LKKLHQQFEM |Q9UQ26-­‐8|RIMS2_HUMAN	  Isoform	  8	  of	  Regulating	  synaptic	  membrane	  exocytosis	  protein	  2	  OS=Homo	  sapiens	  GN=RIMS2 0
HM	  Boost	  Frame	  2 Human 23 25.05 74.7% KLLLHSGVEN |Q8N1W0|YF005_HUMAN	  Transmembrane	  protein	  FLJ37396	  OS=Homo	  sapiens	  PE=2	  SV=2 2,779
HM	  Boost	  Frame	  2 Human 24 Brain	  Lesions 22 25.04 74.7% DNVLHSAFEV |Q13630|FCL_HUMAN	  GDP-­‐L-­‐fucose	  synthase	  OS=Homo	  sapiens	  GN=TSTA3	  PE=1	  SV=1 7,817
Original Human 34 17.35 76.2% HM	  Boost	  Frame	  2 Human 25 25.03 74.7% FSKLHTFEEV |Q96JB1|DYH8_HUMAN	  Dynein	  heavy	  chain	  8,	  axonemal	  OS=Homo	  sapiens	  GN=DNAH8	  PE=1	  SV=2 0
Original Human 47 17.13 75.2% HM	  Boost	  Frame	  2 Human 26 Brain	  Lesions 23 24.91 74.3% QAKLSSFEET |Q5TB80|CE162_HUMAN	  Centrosomal	  protein	  of	  162	  kDa	  OS=Homo	  sapiens	  GN=KIAA1009	  PE=1	  SV=2 0
HM	  Boost	  Frame	  2 Human 27 Brain	  Lesions 24 24.82 74.0% SLALHSVFEG |Q9NY26|S39A1_HUMAN	  Zinc	  transporter	  ZIP1	  OS=Homo	  sapiens	  GN=SLC39A1	  PE=1	  SV=1 0
HM	  Boost	  Frame	  2 Human 28 Brain	  Lesions 25 24.82 74.0% EFALHSLFEA |Q96PN7|TREF1_HUMAN	  Transcriptional-­‐regulating	  factor	  1	  OS=Homo	  sapiens	  GN=TRERF1	  PE=1	  SV=1 0
HM	  Boost	  Frame	  2 Human 29 Brain	  Lesions 26 24.75 73.8% MRHLKSFFEA |Q7Z7H5|TMED4_HUMAN	  Transmembrane	  emp24	  domain-­‐containing	  protein	  4	  OS=Homo	  sapiens	  GN=TMED4	  PE=1	  SV=1 0
HM	  Boost	  Frame	  2 Human 30 Brain	  Lesions 27 24.74 73.8% QKKRHSFLES |Q49MG5|MAP9_HUMAN	  Microtubule-­‐associated	  protein	  9	  OS=Homo	  sapiens	  GN=MAP9	  PE=1	  SV=3 0
Original Human 26 17.53 77.0% HM	  Boost	  Frame	  2 Human 31 Brain	  Lesions 28 24.72 73.7% QKKLHHFFIG |Q8IWB1|IPRI_HUMAN	  Inositol	  1,4,5-­‐trisphosphate	  receptor-­‐interacting	  protein	  OS=Homo	  sapiens	  GN=ITPRIP	  PE=1	  SV=1 0
HM	  Boost	  Frame	  2 Human 32 Brain	  Lesions 29 24.72 73.7% TLSLHSLFEL |Q6U841|S4A10_HUMAN	  Sodium-­‐driven	  chloride	  bicarbonate	  exchanger	  OS=Homo	  sapiens	  GN=SLC4A10	  PE=2	  SV=1 0
HM	  Boost	  Frame	  2 Human 33 Brain	  Lesions 30 24.69 73.7% LRLFHSFEEL |Q9UIY3|RWD2A_HUMAN	  RWD	  domain-­‐containing	  protein	  2A	  OS=Homo	  sapiens	  GN=RWDD2A	  PE=1	  SV=1 0
HM	  Boost	  Frame	  2 Human 34 24.67 73.6% QKFLHSSFVA |Q9UIV8|SPB13_HUMAN	  Serpin	  B13	  OS=Homo	  sapiens	  GN=SERPINB13	  PE=1	  SV=2 0
HM	  Boost	  Frame	  2 Human 35 Brain	  Lesions 31 24.66 73.6% AWLLHSGPEG |O43299|AP5Z1_HUMAN	  AP-­‐5	  complex	  subunit	  zeta-­‐1	  OS=Homo	  sapiens	  GN=AP5Z1	  PE=1	  SV=2 0
HM	  Boost	  Frame	  2 Human 36 24.57 73.3% TKLLHRTEEL |Q68CJ6|SLIP_HUMAN	  Nuclear	  GTPase	  SLIP-­‐GC	  OS=Homo	  sapiens	  GN=NUGGC	  PE=2	  SV=3 0
HM	  Boost	  Frame	  2 Human 37 Brain	  Lesions 32 24.56 73.3% FKTLSSKFEL |Q8WWM7|ATX2L_HUMAN	  Ataxin-­‐2-­‐like	  protein	  OS=Homo	  sapiens	  GN=ATXN2L	  PE=1	  SV=2 0
HM	  Boost	  Frame	  2 Human 38 Brain	  Lesions 33 24.50 73.1% KRRLHLVFEY |Q00532|CDKL1_HUMAN	  Cyclin-­‐dependent	  kinase-­‐like	  1	  OS=Homo	  sapiens	  GN=CDKL1	  PE=1	  SV=5 0
HM	  Boost	  Frame	  2 Human 39 Brain	  Lesions 34 24.47 73.0% EHLLNSGFEV |A7KAX9|RHG32_HUMAN	  Rho	  GTPase-­‐activating	  protein	  32	  OS=Homo	  sapiens	  GN=ARHGAP32	  PE=1	  SV=1 0
HM	  Boost	  Frame	  2 Human 40 24.42 72.9% VMKLLSIFES |Q3B7T1|EDRF1_HUMAN	  Erythroid	  differentiation-­‐related	  factor	  1	  OS=Homo	  sapiens	  GN=EDRF1	  PE=1	  SV=1 0
HM	  Boost	  Frame	  2 Human 41 Brain	  Lesions 35 24.41 72.8% KLELHSSEEA |Q6TFL3|CC171_HUMAN	  Coiled-­‐coil	  domain-­‐containing	  protein	  171	  OS=Homo	  sapiens	  GN=CCDC171	  PE=2	  SV=1 0
HM	  Boost	  Frame	  2 Human 42 24.41 72.8% KLPLHSSEEA |P57721|PCBP3_HUMAN	  Poly(rC)-­‐binding	  protein	  3	  OS=Homo	  sapiens	  GN=PCBP3	  PE=2	  SV=2 0
HM	  Boost	  Frame	  2 Human 43 Brain	  Lesions 36 24.37 72.7% LKRLLSNEEE |O14976|GAK_HUMAN	  Cyclin-­‐G-­‐associated	  kinase	  OS=Homo	  sapiens	  GN=GAK	  PE=1	  SV=2 0
HM	  Boost	  Frame	  2 Human 44 24.24 72.3% TTRLHSLEEK |Q7Z3Z0|K1C25_HUMAN	  Keratin,	  type	  I	  cytoskeletal	  25	  OS=Homo	  sapiens	  GN=KRT25	  PE=1	  SV=1 0
HM	  Boost	  Frame	  2 Human 45 Brain	  Lesions 37 24.20 72.2% HARLHSLEET |Q5T160|SYRM_HUMAN	  Probable	  arginine-­‐-­‐tRNA	  ligase,	  mitochondrial	  OS=Homo	  sapiens	  GN=RARS2	  PE=1	  SV=1 0
HM	  Boost	  Frame	  2 Human 46 Brain	  Lesions 38 24.20 72.2% LPRLHGHFEQ |Q9UPU7|TBD2B_HUMAN	  TBC1	  domain	  family	  member	  2B	  OS=Homo	  sapiens	  GN=TBC1D2B	  PE=1	  SV=2 0
HM	  Boost	  Frame	  2 Human 47 Brain	  Lesions 39 24.18 72.1% VKTLHHKEEV |Q6ZMW2|ZN782_HUMAN	  Zinc	  finger	  protein	  782	  OS=Homo	  sapiens	  GN=ZNF782	  PE=2	  SV=1 0
HM	  Boost	  Frame	  2 Human 48 Brain	  Lesions 40 24.17 72.1% SPSLHSREEA |B7Z7H5|B7Z7H5_HUMAN	  Coiled-­‐coil	  domain-­‐containing	  protein	  116	  OS=Homo	  sapiens	  GN=CCDC116	  PE=2	  SV=1 0
HM	  Boost	  Frame	  2 Human 49 Brain	  Lesions 41 24.16 72.1% PRKLHWLFEL |Q14997|PSME4_HUMAN	  Proteasome	  activator	  complex	  subunit	  4	  OS=Homo	  sapiens	  GN=PSME4	  PE=1	  SV=2 0
HM	  Boost	  Frame	  2 Human 50 24.14 72.0% LKKLLSFAEN |Q5W041|ARMC3_HUMAN	  Armadillo	  repeat-­‐containing	  protein	  3	  OS=Homo	  sapiens	  GN=ARMC3	  PE=2	  SV=2 0
Table S2. GDP-L-fucose synthase, Myelin and CEF Peptides
GDP-L-fucose synthase
GDP-L-fucose synthase 1-15 MGEPQGSMRILVTGG 
GDP-L-fucose synthase 6-20 GSMRILVTGGSGLVG
GDP-L-fucose synthase 11-25 LVTGGSGLVGKAIQK
GDP-L-fucose synthase 16-30 SGLVGKAIQKVVADG
GDP-L-fucose synthase 21-35 KAIQKVVADGAGLPG
GDP-L-fucose synthase 26-40 VVADGAGLPGEDWVF
GDP-L-fucose synthase 31-45 AGLPGEDWVFVSSKD
GDP-L-fucose synthase 36-50 EDWVFVSSKDADLTD
GDP-L-fucose synthase 41-55 VSSKDADLTDTAQTR
GDP-L-fucose synthase 46-60 ADLTDTAQTRALFEK
GDP-L-fucose synthase 51-65 TAQTRALFEKVQPTH
GDP-L-fucose synthase 56-70 ALFEKVQPTHVIHLA
GDP-L-fucose synthase 61-75 VQPTHVIHLAAMVGG
GDP-L-fucose synthase 66-80 VIHLAAMVGGLFRNI
GDP-L-fucose synthase 71-85 AMVGGLFRNIKYNLD
GDP-L-fucose synthase 76-90 LFRNIKYNLDFWRKN
GDP-L-fucose synthase 81-95 KYNLDFWRKNVHMND
GDP-L-fucose synthase 86-100 FWRKNVHMNDNVLHS
GDP-L-fucose synthase 91-105 VHMNDNVLHSAFEVG
GDP-L-fucose synthase 96-110 NVLHSAFEVGARKVV
GDP-L-fucose synthase 101-115 AFEVGARKVVSCLST
GDP-L-fucose synthase 106-120 ARKVVSCLSTCIFPD
GDP-L-fucose synthase 111-125 SCLSTCIFPDKTTYP
GDP-L-fucose synthase 116-130 CIFPDKTTYPIDETM
GDP-L-fucose synthase 121-135 KTTYPIDETMIHNGP
GDP-L-fucose synthase 126-140 IDETMIHNGPPHNSN
GDP-L-fucose synthase 131-145 IHNGPPHNSNFGYSY
GDP-L-fucose synthase 136-150 PHNSNFGYSYAKRMI
GDP-L-fucose synthase 141-155 FGYSYAKRMIDVQNR
GDP-L-fucose synthase 146-160 AKRMIDVQNRAYFQQ
GDP-L-fucose synthase 151-165 DVQNRAYFQQYGCTF
GDP-L-fucose synthase 156-170 AYFQQYGCTFTAVIP
GDP-L-fucose synthase 161-175 YGCTFTAVIPTNVFG
GDP-L-fucose synthase 166-180 TAVIPTNVFGPHDNF
GDP-L-fucose synthase 171-185 TNVFGPHDNFNIEDG
GDP-L-fucose synthase 176-190 PHDNFNIEDGHVLPG
GDP-L-fucose synthase 181-195 NIEDGHVLPGLIHKV
GDP-L-fucose synthase 186-200 HVLPGLIHKVHLAKS
GDP-L-fucose synthase 191-205 LIHKVHLAKSSGSAL
GDP-L-fucose synthase 196-210 HLAKSSGSALTVWGT
GDP-L-fucose synthase 201-215 SGSALTVWGTGNPRR
GDP-L-fucose synthase 206-220 TVWGTGNPRRQFIYS
GDP-L-fucose synthase 211-225 GNPRRQFIYSLDLAQ
GDP-L-fucose synthase 216-230 QFIYSLDLAQLFIWV
GDP-L-fucose synthase 221-235 LDLAQLFIWVLREYN
GDP-L-fucose synthase 226-240 LFIWVLREYNEVEPI
GDP-L-fucose synthase 231-245 LREYNEVEPIILSVG
GDP-L-fucose synthase 236-250 EVEPIILSVGEEDEV
GDP-L-fucose synthase 241-255 ILSVGEEDEVSIKEA
GDP-L-fucose synthase 246-260 EEDEVSIKEAAEAVV
GDP-L-fucose synthase 251-265 SIKEAAEAVVEAMDF
GDP-L-fucose synthase 256-270 AEAVVEAMDFHGEVT
GDP-L-fucose synthase 261-275 EAMDFHGEVTFDTTK
GDP-L-fucose synthase 266-280 HGEVTFDTTKSDGQF
GDP-L-fucose synthase 271-285 FDTTKSDGQFKKTAS
GDP-L-fucose synthase 276-290 SDGQFKKTASNSKLR
GDP-L-fucose synthase 281-295 KKTASNSKLRTYLPD
GDP-L-fucose synthase 286-300 NSKLRTYLPDFRFTP
GDP-L-fucose synthase 291-305 TYLPDFRFTPFKQAV
GDP-L-fucose synthase 296-310 FRFTPFKQAVKETCA
GDP-L-fucose synthase 301-315 FKQAVKETCAWFTDN

































Table S3.  Peptides from brain proteins identified by proteomic analysis in brain tissue.
Protein UniProt Peptide Sequence Residues MS WM MS GM HD WM HD GM
Myelin basic protein P02686 ASTNSETNRGESEK 15 - 28 14 14 - 14
NLGELSR 31 - 37 - 3 - -
NAWQDAHPADPGSRPHLIR 75 - 93 - 2 - 2
DAPGREDNTFK 98 - 108 4 4 - 4
DRPSESDELQTIQEDSAATSESLDVMASQK 109 - 138 - 6 - 6
HGSKYLATASTMDHAR 144 - 159 18 18 18 -
    YLATASTMDHAR 148 - 159 35 35 35 35
    YLATASTMDHARHGFLPR 148 - 165 46 46 46 46
    YLATASTMDHARHGFLPRHR 148 - 167 11 11 11 11
    YLATASTMDHARHGFLPRHRDTGILDSIGR 148 - 177 9 - 9 -
                HGFLPR 160 - 165 12 12 12 12
                HGFLPRHR 160 - 167 13 13 13 13
                HGFLPRHRDTGILDSIGR 160 - 177 16 - 16 16
                HGFLPRHRDTGILDSIGRFFGGDR 160 - 187 - - 1 -
                HGFLPRHRDTGILDSIGRFFGGDRGAPK 160 - 191 4 - 4 -
                      HRDTGILDSIGR 166 - 177 29 29 29 29
                      HRDTGILDSIGRFFGGDR 166 - 187 20 20 20 20
                      HRDTGILDSIGRFFGGDRGAPK 166 - 191 25 25 25 25
                      HRDTGILDSIGRFFGGDRGAPKR 166 - 192 - - 2 -
                        DTGILDSIGR 168 - 177 14 14 14 14
                        DTGILDSIGRFFGGDR 168 - 183 21 21 21 21
                        DTGILDSIGRFFGGDRGAPK 168 - 187 21 21 21 21
                        DTGILDSIGRFFGGDRGAPKR 168 - 188 2 - 2 -
                        DTGILDSIGRFFGGDRGAPKRGSGK 168 - 192 2 - 2 -
                                  FFGGDR 178 - 183 8 8 8 8
                                  FFGGDRGAPK 178 - 187 24 24 24 24
                                  FFGGDRGAPKR 178 - 188 5 - 5 -
                                  FFGGDRGAPKRGSGK 178 - 192 2 - 2 -
                                  FFGGDRGAPKRGSGKDSHHPAR 178 - 199 - - 2 -
                                            RGSGKDSHHPAR 188 - 199 2 - - -
                                            RGSGKDSHHPARTAHYGSLPQK 188 - 209 9 9 9 9
                                             GSGKDSHHPARTAHYGSLPQK 189 - 209 2 - 2 -
                                                 DSHHPARTAHYGSLPQK 193 - 209 28 28 28 28
                                                 DSHHPARTAHYGSLPQKSHGR 193 - 213 3 - 3 -
                                                 DSHHPARTAHYGSLPQKSHGRTQDENPVVHFFK 193 - 225 1 - - -
                                                        TAHYGSLPQK 200 - 209 21 21 21 21
                                                        TAHYGSLPQKSHGR 200 - 213 21 21 21 21
                                                        TAHYGSLPQKSHGRTQDENPVVHFFK 200 - 225 11 - 11 11
                                                                  SHGRTQDENPVVHFFK 210 - 225 37 37 37 37
                                                                  SHGRTQDENPVVHFFKNIVTPR 210 - 231 4 - 4 -
                                                                  SHGRTQDENPVVHFFKNIVTPRTPPPSQGK 210 - 239 - - 1 -
                                                                      TQDENPVVHFFK 214 - 225 34 34 34 34
                                                                      TQDENPVVHFFKNIVTPR 214 - 231 27 27 27 27
                                                                      TQDENPVVHFFKNIVTPRTPPPSQGK 214 - 239 9 9 9 9
                                                                                  NIVTPR 226 - 231 10 10 10 10
                                                                                  NIVTPRTPPPSQGK 226 - 239 62 62 62 62
                                                                                  NIVTPRTPPPSQGKGRGLSLSR 226 - 247 - - 1 -
                                                                                        TPPPSQGK 232 - 239 3 - - -
                                                                                        TPPPSQGKGR 232 - 241 - - 3 -
                                                                                        TPPPSQGKGRGLSLSR 232 - 247 - - 1 -
                                                                                                GRGLSLSR 240 - 247 12 12 12 -
                                                                                                GRGLSLSRFSWGAEGQRPGFGYGGR 240 - 264 13 13 13 -
                                                                                                GRGLSLSRFSWGAEGQRPGFGYGGRASDYK 240 - 269 10 - 10 -
                                                                                                  GLSLSRFSWGAEGQRPGFGYGGR 242 -264 14 14 14 14
                                                                                                  GLSLSRFSWGAEGQRPGFGYGGRASDYK 242 - 269 6 6 6 -
                                                                                                        FSWGAEGQRPGFGYGGR 248 - 264 35 35 35 35
                                                                                                        FSWGAEGQRPGFGYGGRASDYK 248 - 269 35 35 35 35
                                                                                                        FSWGAEGQRPGFGYGGRASDYKSAHK 248 - 273 7 - 7 -
                                                                                                                         ASDYKSAHKGFK 265 - 276 3 - 3 -
                                                                                                                         ASDYKSAHKGFKGVDAQGTLSK 265 - 286 2 - 2 -
                                                                                                                              SAHKGFKGVDAQGTLSK 270 - 286 6 - 6 -
                                                                                                                              SAHKGFKGVDAQGTLSKIFK 270 - 289 - - 1 -
                                                                                                                                  GFKGVDAQGTLSK 274 - 286 18 18 18 18
                                                                                                                                  GFKGVDAQGTLSKIFK 274 - 289 - - 2 -
                                                                                                                                  GFKGVDAQGTLSKIFKLGGRDSR 274 - 296 - - 1 -
                                                                                                                                     GVDAQGTLSK 277 - 286 24 24 24 24
                                                                                                                                     GVDAQGTLSKIFK 277 - 289 9 - 9 9
                                                                                                                                     GVDAQGTLSKIFKLGGR 277 - 293 - - 1 -
                                                                                                                                     GVDAQGTLSKIFKLGGRDSR 277 - 296 3 - 3 -
                                                                                                                                               IFKLGGR 287 - 293 5 - 5 -
                                                                                                                                               IFKLGGRDSR 287 - 296 4 - 4 -
                                                                                                                                               IFKLGGRDSRSGSPMAR 287 - 303 3 - 3 -
                                                                                                                                               IFKLGGRDSRSGSPMARR 287 - 304 3 - 3 -
                                                                                                                                                  LGGRDSR 292 - 296 2 - 2 -
                                                                                                                                                  LGGRDSRSGSPMAR 292 - 303 45 45 45 45
                                                                                                                                                  LGGRDSRSGSPMARR 292 - 304 10 - 10 10
                                                                                                                                                      DSRSGSPMAR 294 - 303 41 41 41 41
                                                                                                                                                      DSRSGSPMARR 294 - 304 11 11 11 11
                                                                                                                                                         SGSPMAR 297 - 303 24 24 24 24
                                                                                                                                                         SGSPMARR 297 - 304 9 9 9 9
993 871 985 865
Myelin proteolipid protein P60201 LIETYFSK 46 - 53 12 12 12 12
QIFGDYK 99 - 105 15 15 15 15
GLSATVTGGQK 112 - 122 24 24 24 24
GLSATVTGGQKGR 112 - 124 14 14 14 14
GLSATVTGGQKGRGSR 112 - 127 4 - 4 -
           GRGSRGQHQAHSLER 123 - 137 4 4 - 4
             GSRGQHQAHSLER 125 - 137 - 9 - 9
                GQHQAHSLER 128 - 137 15 15 - 15
VCHCLGK 138 - 144 - - - 3
TSASIGSLCADAR 193 - 205 12 12 12 12
TSASIGSLCADARMYGVLPWNAFPGK 193 - 218 - - - 1
             MYGVLPWNAFPGK 206 - 218 48 48 48 48
VCGSNLLSICK 219 - 229 - 9 - 9
148 153 129 157
Myelin-oligodendrocyte glycoprotein Q16653 VIGPRHPIR 34 - 42 3 - 3 3
VIGPRHPIRALVGDEVELPCR 34 - 54 1 - - -
     HPIRALVGDEVELPCR 39 - 54 - - - 3
         ALVGDEVELPCR 43 - 54 12 12 12 12
         ALVGDEVELPCRISPGK 43 - 59 - - - 1
VVHLYR 76 - 81 11 11 11 11
VVHLYRNGK 76 - 84 12 12 12 12
VVHLYRNGKDQDGDQAPEYR 76 - 95 15 15 15 15
VVHLYRNGKDQDGDQAPEYRGRTELLK 76 - 102 5 - 5 5
      NGKDQDGDQAPEYR 82 - 95 31 31 31 31
      NGKDQDGDQAPEYRGR 82 - 97 4 - 4 -
      NGKDQDGDQAPEYRGRTELLK 82 - 102 2 - 2 -
         DQDGDQAPEYR 85 - 95 12 12 12 12
         DQDGDQAPEYRGR 85 - 97 9 - 9 9
         DQDGDQAPEYRGRTELLK 85 - 102 4 - 4 4
                    GRTELLKDAIGEGK 96 - 109 - 2 - -
                    GRTELLKDAIGEGKVTLR 96 - 113 - - 1 -
                           DAIGEGKVTLR 103 - 113 9 9 9 -
                           DAIGEGKVTLRIR 103 - 115 - - 2 -
FSDEGGFTCFFR 119 - 130 12 12 12 12
DHSYQEEAAMELK 131 - 143 24 24 24 24
LRAEIENLHR 186 - 195 13 13 13 13
  AEIENLHR 188 - 195 12 12 12 12
TFDPHFLR 196 - 203 5 5 - 5
RLAGQFLEELR 234 - 244 - - - 3
RLAGQFLEELRNPF 234 - 247 8 8 8 8
 LAGQFLEELR 235 - 244 - 9 9 9
 LAGQFLEELRNPF 235 - 247 12 12 12 12
216 199 222 216
Myelin-associated glycoprotein P20916 FDFPDELRPAVVHGVWYFNSPYPK 44 - 67 12 12 12 12
NYPPVVFK 68 - 75 12 12 12 12
SRTQVVHESFQGR 76 - 88 10 10 10 10
SRTQVVHESFQGRSR 76 - 90 1 - - -
  TQVVHESFQGR 78 - 88 12 12 12 12
LLGDLGLR 91 - 98 12 12 12 12
LREDEGTWVQVSLLHFVPTR 189 - 208 13 13 13 13
  EDEGTWVQVSLLHFVPTR 191 - 208 - 6 - 6
DGTVLR 276 - 281 4 4 4 4
DTVQCLCVVK 426 - 435 - 6 - 6
SNPEPSVAFELPSR 436 - 449 9 9 - 9
EFVYSER 459 - 465 8 8 8 8
SGLVLTSILTLR 466 - 477 12 12 12 12
SGLVLTSILTLRGQAQAPPR 466 - 485 3 - - -
            GQAQAPPR 478 - 485 12 12 12 12
VICTAR 486 - 491 - - - 2
NLYGAK 492 - 497 2 - 2 -
SLELPFQGAHR 498 - 508 12 12 12 12
NVTESPSFSAGDNPPVLFSSDFR 541 - 563 12 12 12 12
NVTESPSFSAGDNPPVLFSSDFRISGAPEK 541 - 570 7 7 7 7
                       ISGAPEK 564 - 570 3 - - -
                       ISGAPEKYESER 564 - 575 12 12 12 12
                       ISGAPEKYESERR 564 - 576 2 - 2 -
                       ISGAPEKYESERRLGSER 564 - 581 - - 2 -
                              YESERRLGSER 571 - 581 6 6 6 6
                              YESERRLGSERR 571 - 582 - - - 1
                                   RLGSERRLLGLR 576 - 587 2 - 2 -
                                         RLLGLR 582 - 587 9 9 9 9
                                         RLLGLRGEPPELDLSYSHSDLGK 582 - 604 12 12 12 12
                                          LLGLRGEPPELDLSYSHSDLGK 583 - 604 10 10 10 10
                                          LLGLRGEPPELDLSYSHSDLGKRPTK 583 - 608 2 - 2 -
                                               GEPPELDLSYSHSDLGK 588 - 604 12 12 12 12
DSYTLTEELAEYAEIR 609 - 624 12 12 12 12
DSYTLTEELAEYAEIRVK 609 - 626 8 - - 8
243 232 221 243
Myelin-associated oligodendrocyte basic protein Q13875 QQPAAPPAVVR 82 - 92 12 12 12 12
QQPAAPPAVVRAPAKPR 82 - 98 - - 3 -
QPRPRPEVRPPPAK 136 - 149 - - 2 2
SSPLRGPGASR 162 - 172 2 - 2 -
SSPLRGPGASRGGSPVK 162 - 178 6 - 6 -
     GPGASRGGSPVK 167 - 178 - - 2 -
20 12 27 14
Oligodendrocyte myelin glycoprotein P23515 TLDISNNR 82 - 90 12 12 12 12
TLDISNNRLESLPAHLPR 82 - 99 18 18 18 18
        LESLPAHLPR 91 - 99 12 12 12 12
SDTAYQWNLK 117 - 126 12 12 12 12
YLDVSK 127 - 132 8 8 8 8
VVLIKNTLR 138 - 146 - 9 9 9
SLEVLNLSSNK 147 - 157 12 12 12 12
LWTVPTNMPSK 158 - 168 22 22 22 22
FTFIPDQSFDQLFQLQEITLYNNR 203 - 226 14 14 14 14
WSCDHK 227 - 232 - 2 - 2
WMMETK 241 - 246 17 17 17 17
AHVIGTPCSTQISSLK 247 - 262 9 9 - 9
ETTFGATLSK 311 - 320 8 8 - 8
144 155 136 155
Proteome data correspond to white matter (WM) and grey matter (GM) from multiple sclerosis patients (MS, n=15) and healthy donors (HD, n=9). In bold are GDP-L-fucose synthase values.
Table S4. Patient Classification and HLA binding
A Peptide 161-175 51-65 136-150 251-265 241-255 246-260 26-40 226-240 236-250 256-270 296-310 1-15 76-90 156-170 121-135 131-145 166-180 231-245 261-275 271-285 Log10 SI Wsum
66JO 0.96 1.12 0.92 0.78 0.59 0.70 1.08 1.00 0.69 0.91 0.47 1.02 0.81 0.94 0.96 1.03 0.61 0.73 0.70 0.60 0.00 Nonresponder
103FH 0.87 0.73 0.80 0.58 0.67 0.61 0.70 0.81 0.68 0.83 0.69 0.73 0.75 0.78 0.64 0.62 0.79 0.96 0.70 0.82 0.00 Nonresponder
204AM 0.87 0.77 0.69 0.87 0.86 0.76 0.70 1.10 0.79 0.94 0.44 0.89 1.14 0.94 0.64 0.97 0.84 0.89 0.72 0.93 0.00 Nonresponder
247PE 0.78 0.78 0.72 0.61 0.65 0.73 0.73 0.65 0.74 0.75 0.69 0.87 0.74 0.69 0.70 0.70 0.72 0.59 0.73 0.65 0.00 Nonresponder
381MA 1.31 0.76 1.13 1.00 1.00 1.06 0.82 1.27 0.93 0.98 0.95 0.85 0.72 1.23 1.00 1.03 1.06 0.99 0.84 1.24 0.00 Nonresponder
702AN 0.62 0.50 0.63 0.61 0.64 0.58 0.68 0.64 0.55 0.53 0.54 0.69 0.57 0.69 0.56 0.41 0.51 0.56 0.51 0.55 0.00 Nonresponder
740RA 0.99 0.78 0.70 0.81 0.77 0.80 0.89 0.86 0.75 0.59 0.66 0.86 0.82 0.81 0.67 0.68 0.84 0.81 0.64 0.95 0.00 Nonresponder
936MA 0.68 0.66 0.83 0.95 0.97 1.11 0.65 0.82 1.03 1.01 1.04 0.73 0.67 0.72 0.72 0.90 0.63 0.98 0.96 1.02 0.00 Nonresponder
973JO 0.85 0.91 0.37 0.50 0.68 0.57 0.56 0.90 0.62 0.56 0.70 0.83 0.47 0.85 0.61 0.50 1.02 0.72 0.49 0.69 0.00 Nonresponder
1125PA 0.81 1.07 0.43 0.57 0.63 0.49 0.99 0.49 0.54 0.73 0.41 0.74 0.43 0.58 0.74 0.61 0.93 0.71 0.65 0.50 0.00 Nonresponder
1292DI 1.09 0.76 0.47 0.93 0.81 0.66 0.63 0.54 0.92 0.40 0.72 0.87 0.57 0.86 0.65 0.75 0.90 1.06 0.64 0.93 0.00 Nonresponder
1300EV 1.21 0.90 0.89 0.97 0.59 0.70 0.51 0.73 0.88 0.61 0.75 0.59 0.70 0.86 0.90 0.91 1.11 0.92 0.74 0.98 0.00 Nonresponder
897UR 1.25 1.05 0.70 0.76 0.89 1.10 0.95 0.99 0.87 0.79 0.86 0.66 0.79 0.88 0.74 0.65 0.88 0.79 0.81 0.72 0.00 Nonresponder
127RO 0.86 0.67 0.63 1.08 1.03 1.15 0.62 0.65 0.86 0.98 0.94 0.62 0.65 0.70 0.80 0.70 0.54 0.88 0.84 1.01 0.00 Nonresponder
1290JA 1.17 0.91 1.06 1.08 1.19 1.34 0.88 0.98 1.34 1.18 1.10 1.02 0.72 1.13 0.87 0.98 0.74 1.01 0.94 1.41 0.00 Nonresponder
800TH 1.08 0.94 0.97 0.94 0.80 0.99 0.74 0.84 0.86 0.72 0.57 0.92 0.51 0.72 0.88 0.89 0.88 0.98 0.74 0.76 0.00 Nonresponder
830OL 0.67 0.81 0.99 0.71 0.98 0.93 0.68 0.43 0.81 0.67 0.85 1.06 0.69 0.85 0.89 0.93 0.73 0.79 0.69 0.84 0.00 Nonresponder
818MA 1.42 1.10 0.96 1.10 1.06 1.09 1.01 1.03 0.92 1.43 0.99 0.82 0.80 1.17 0.90 0.97 1.05 0.90 1.47 1.30 0.17 Nonresponder
1206CO 1.03 1.11 0.64 0.72 0.77 0.62 0.91 0.89 0.87 0.84 0.62 0.79 0.67 1.01 1.03 0.98 1.47 0.94 0.60 0.77 0.17 Nonresponder
780UR 1.09 0.84 0.90 0.76 0.88 0.76 1.11 1.54 0.91 0.91 0.68 1.05 0.78 0.94 0.90 0.90 0.85 0.76 0.84 0.82 0.79 Moderate Responder
866JE 1.32 0.87 1.03 1.60 0.87 0.81 0.97 0.97 1.03 1.11 0.79 0.80 0.68 0.98 0.92 0.92 0.93 0.93 0.92 1.12 0.98 Moderate Responder
748UR 1.48 0.83 1.11 1.42 0.94 1.01 0.80 1.02 0.88 0.98 0.92 0.83 0.89 1.24 0.87 1.05 0.97 0.83 1.10 1.13 1.01 Moderate Responder
1346JU 1.44 0.88 1.49 0.73 0.86 0.79 1.13 1.01 0.93 0.67 0.95 1.04 0.46 1.26 1.12 1.47 0.97 0.68 0.74 0.94 1.02 Moderate Responder
1081SA 1.63 0.81 1.32 1.10 1.30 1.45 1.01 0.95 1.47 1.30 1.09 1.25 0.95 1.25 1.48 1.28 1.27 1.63 1.38 1.47 1.34 Moderate Responder
817JD 1.53 1.31 1.12 1.09 0.06 1.01 4.09 0.98 0.95 1.23 1.05 0.97 0.87 1.25 1.10 1.06 0.97 0.82 0.84 0.82 1.43 Moderate Responder
1129RE 1.47 1.55 1.70 1.65 1.55 1.47 1.09 1.10 1.26 1.30 1.90 1.33 0.93 1.12 0.88 0.78 0.92 0.98 0.78 1.05 1.81 High Responder
1005ME 1.20 1.87 1.91 1.95 1.83 2.04 1.57 1.30 1.78 2.85 1.95 1.02 2.14 0.97 0.77 0.88 0.76 0.82 1.24 0.93 2.00 High Responder
1173DI 2.30 1.81 2.42 2.63 2.09 2.27 1.34 0.56 1.39 1.96 1.39 1.67 0.82 1.64 0.74 0.92 0.91 0.78 0.57 0.69 2.09 High Responder
718MA 4.57 1.56 0.89 0.79 0.80 0.95 0.69 25.93 0.73 0.65 0.91 1.22 0.69 0.75 1.03 1.14 1.25 0.80 0.62 0.90 2.16 High Responder
816DA 3.50 4.77 8.21 4.27 2.03 3.76 3.04 1.59 1.49 4.65 1.99 1.70 1.62 5.21 0.80 0.94 0.88 0.56 1.16 0.89 2.38 High Responder
776JE 2.35 4.37 7.40 6.99 6.24 7.04 4.76 2.44 4.52 6.41 4.81 2.50 1.53 4.55 1.01 0.95 0.93 0.93 1.01 1.05 2.50 High Responder
Peptide Sum 8 6 6 6 5 5 4 4 4 4 4 3 3 3 1 1 1 1 1 1
B
Binding Affinity (percentile-rank)*
37.47 13.48 29.81 68.2 29.81 75.22 16.25 21.74 39.16 43.26 39.06 61.74 4.67 10.49 2.79 11.29 60.77 33.2 20.11 41.85
8.36 2.14 74.35 61.77 74.52 94.52 83.08 91.67 19.12 86.02 43.48 77.96 10.58 51.08 65.44 93.75 86.86 19.8 70.27 82.89
Red cells med SI > 1.455.




Table	  S5.	  Bacteria	  selected	  for	  GDP-­‐L-­‐fucose	  synthase	  comparison
GDP	  fucose	  synthase
Bacterial	  species Relevance	  in	  MS Reference sequences	  analyzed	  (NCBI)
Acinetobacter	  calcoaceticus Gut	  microbiota Increased	  in	  MS	  patients Cekanaviciute	  E,	  Proceedings	  of	  ECTRIMS,	  2016 Not	  found
Adlercreutzia Gut	  microbiota Decreased	  in	  RRMS	  patients Chen	  J,	  Sci	  Rep,	  2016 Not	  found
Akkermansia	  muciniphila Gut	  microbiota Increased	  in	  MS	  patients Jangi	  S,	  Nat	  Comm,	  2016 Akkermansia	  KLE1798,	  1797,	  1605,	  CAG:304	  (present	  in	  gut)
Anaerostipes	  hadrus Gut	  microbiota Decreased	  in	  Japanese	  RRMS	  patients Miyake	  S,	  Plos	  one,	  2015 Not	  found
Bacteroides	  coprocola Gut	  microbiota Decreased	  in	  Japanese	  RRMS	  patients Miyake	  S,	  Plos	  one,	  2015 Not	  found
Bacteroides	  coprophilus Gut	  microbiota Decreased	  in	  Japanese	  RRMS	  patients Miyake	  S,	  Plos	  one,	  2015 Not	  found
Bacteroides	  fragilis Gut	  microbiota Oral	  administration	  lowers	  clinical	  score	  in	  EAE	  by	  polysaccharide	  A Ochoa-­‐Reparaz	  J,	  J	  Immunol	  2010 Bacteroides	  fragilis
Bacteroides	  stercoris Gut	  microbiota Decreased	  in	  Japanese	  RRMS	  patients Miyake	  S,	  Plos	  one,	  2015 Bacteroides	  stercoris
Bifidobacterium Gut	  microbiota Increased	  in	  pediatric	  MS	  patients Tremlett	  H,	  Eur	  J	  Neurol,	  2016 Not	  found
Bilophilia Gut	  microbiota Increased	  in	  pediatric	  MS	  patients Tremlett	  H,	  Eur	  J	  Neurol,	  2016 Not	  found
Blautia Gut	  microbiota Increased	  in	  RRMS	  patients Chen	  J,	  Sci	  Rep,	  2016 Blautia	  obeum	  and	  Blautia	  wexlerae	  (present	  in	  gut)
butyrate-­‐producing	  bacterium	  A2-­‐175 Gut	  microbiota Decreased	  in	  Japanese	  RRMS	  patients Miyake	  S,	  Plos	  one,	  2015 Not	  found
butyrate-­‐producing	  bacterium	  SL7/1 Gut	  microbiota Decreased	  in	  Japanese	  RRMS	  patients Miyake	  S,	  Plos	  one,	  2015 Not	  found
Butyricimonas	  synergistica Gut	  microbiota Decreased	  in	  MS	  patients Jangi	  S,	  Nat	  Comm,	  2016 Not	  found
Christensenellaceae Gut	  microbiota Increased	  in	  pediatric	  MS	  patients Tremlett	  H,	  Eur	  J	  Neurol,	  2016 Not	  found
Clostridiaceae	  bacterium	  SH032 Gut	  microbiota Decreased	  in	  Japanese	  RRMS	  patients Miyake	  S,	  Plos	  one,	  2015 Not	  found
Clostridium	  perfringens	  type	  A Gut	  microbiota Decreased	  in	  MS	  patients Rumah	  KR,	  Plos	  one	  2013 Not	  found
Clostridium	  perfringens	  type	  B Gut	  microbiota Found	  in	  human	  for	  the	  first	  time	  in	  a	  MS	  patient	  at	  the	  disease	  onset Rumah	  KR,	  Plos	  one	  2013 Not	  found
Clostridium	  sp. Gut	  microbiota Decreased	  in	  Japanese	  RRMS	  patients Miyake	  S,	  Plos	  one,	  2015 Clostridium	  strain	  KLE1755	  (present	  in	  gut)
Clostridium	  sp.	  ID5 Gut	  microbiota Decreased	  in	  Japanese	  RRMS	  patients Miyake	  S,	  Plos	  one,	  2015 Not	  found
Clostridium	  sp.	  RT8 Gut	  microbiota Decreased	  in	  Japanese	  RRMS	  patients Miyake	  S,	  Plos	  one,	  2015 Not	  found
Collinsella	  aerofaciens Gut	  microbiota Decreased	  in	  MS	  patients	  untreated Jangi	  S,	  Nat	  Comm,	  2016 Not	  found
Desulfotomaculum	  sp.	  CYP1 Gut	  microbiota Decreased	  in	  Japanese	  RRMS	  patients Miyake	  S,	  Plos	  one,	  2015 Not	  found
Desulfovibrio Gut	  microbiota Increased	  in	  pediatric	  MS	  patients Tremlett	  H,	  Eur	  J	  Neurol,	  2016 Several	  strains
Dorea Gut	  microbiota Increased	  in	  RRMS	  patients Chen	  J,	  Sci	  Rep,	  2016 Not	  found
Eubacterium	  rectale	  ATCC	  33656 Gut	  microbiota Decreased	  in	  Japanese	  RRMS	  patients Miyake	  S,	  Plos	  one,	  2015 Not	  found
Faecalibacterium	  prausnitzii Gut	  microbiota Decreased	  in	  Japanese	  RRMS	  patients Miyake	  S,	  Plos	  one,	  2015 Not	  found
Fusobacterium Gut	  microbiota Absence	  associated	  to	  shorter	  time	  to	  relapse	  in	  pediatric	  MS Tremlett	  H,	  J	  Neurol	  Sci,	  2016 Not	  found
Haemophilus Gut	  microbiota Increased	  in	  RRMS	  patients Chen	  J,	  Sci	  Rep,	  2016 Not	  found
Lachnospira	  pectinoschiza Gut	  microbiota Decreased	  in	  Japanese	  RRMS	  patients Miyake	  S,	  Plos	  one,	  2015 Not	  found
Lachnospiraceae Gut	  microbiota Decreased	  in	  pediatric	  MS	  patients Tremlett	  H,	  Eur	  J	  Neurol,	  2016 Lachnospiraceae	  bacterium	  3-­‐1	  (present	  in	  gut)
Lactobacillus	  rogosae Gut	  microbiota Decreased	  in	  Japanese	  RRMS	  patients Miyake	  S,	  Plos	  one,	  2015 Not	  found
Lepotrichia Gut	  microbiota Absence	  associated	  to	  shorter	  time	  to	  relapse	  in	  pediatric	  MS Tremlett	  H,	  J	  Neurol	  Sci,	  2016 Not	  found
Megamonas	  funiformis	  YIT	  11815 Gut	  microbiota Decreased	  in	  Japanese	  RRMS	  patients Miyake	  S,	  Plos	  one,	  2015 Not	  found
Methanobrevibacter	  smithii Gut	  microbiota Increased	  in	  MS	  patients Jangi	  S,	  Nat	  Comm,	  2016 Not	  found
Mycoplana Gut	  microbiota Increased	  in	  RRMS	  patients Chen	  J,	  Sci	  Rep,	  2016 Not	  found
Parabacteroides Gut	  microbiota Decreased	  in	  RRMS	  patients Chen	  J,	  Sci	  Rep,	  2016 Parabacteroides	  distastonis
Parabacteroides	  distasonis Gut	  microbiota Decreased	  in	  MS	  patients Baranzini	  S	  data Parabacteroides	  distastonis
Prevotella Gut	  microbiota Decreased	  in	  RRMS	  patients Chen	  J,	  Sci	  Rep,	  2016 Several	  strains
Prevotella	  copri	  DSM	  18205 Gut	  microbiota Decreased	  in	  Japanese	  RRMS	  patients Miyake	  S,	  Plos	  one,	  2015 Not	  found
Prevotella	  stercorea Gut	  microbiota Decreased	  in	  MS	  patients	  untreated Jangi	  S,	  Nat	  Comm,	  2016 Not	  found
Pseudomonas Gut	  microbiota Increased	  in	  RRMS	  patients Chen	  J,	  Sci	  Rep,	  2016 Several	  strains
Roseburia	  sp.1120 Gut	  microbiota Decreased	  in	  Japanese	  RRMS	  patients Miyake	  S,	  Plos	  one,	  2015 Not	  found
Ruminococcaceae Gut	  microbiota Decreased	  in	  pediatric	  MS	  patients Tremlett	  H,	  Eur	  J	  Neurol,	  2016 Not	  found
Sarcina	  ventriculi Gut	  microbiota Decreased	  in	  treated	  vs	  untreaded	  MS	  patients Jangi	  S,	  Nat	  Comm,	  2016 Not	  found
Slackia	  isoflavoniconvertens Gut	  microbiota Decreased	  in	  MS	  patients	  untreated Jangi	  S,	  Nat	  Comm,	  2016 Not	  found
Streptococcus	  thermophiles/salivarius Gut	  microbiota Increased	  in	  Japanese	  RRMS	  patients Miyake	  S,	  Plos	  one,	  2015 Not	  found
Sutterella	  stercoricanis Gut	  microbiota Increased	  in	  treated	  vs	  untreated	  MS	  patients Jangi	  S,	  Nat	  Comm,	  2016 Not	  found
Sutterella	  wadsworthensis Gut	  microbiota Increased	  in	  treated	  vs	  untreated	  MS	  patients Jangi	  S,	  Nat	  Comm,	  2016 Not	  found
Sutterella	  wadsworthensis	  2_1_59BFAA Gut	  microbiota Decreased	  in	  Japanese	  RRMS	  patients Miyake	  S,	  Plos	  one,	  2015 Not	  found
Enterococcus faecium Gut	  microbiota	  (Pathogen) Enterococcus faecalis
Escherichia coli Gut	  microbiota	  (Pathogen) Escherichia coli
Helicobacter pylori Gut	  microbiota	  (Pathogen) Helicobacter pylori
Klebsiella pneumoniae Gut	  microbiota	  (Pathogen) Klebsiella pneumoniae
Campylobacter jejuni Pathogen Campylobacter jejuni
Mycobacterium avium Pathogen Mycobacterium avium
Mycobacterium tuberculosis Pathogen Mycobacterium tuberculosis
Porphyromonas gingivalis Pathogen Porphyromonas gingivalis
Pseudomonas sp Pathogen Pseudomonas sp
Salmonella enterica Pathogen Salmonella enterica
Shigella flexneri Pathogen Shigella flexneri
Shigella sonnei Pathogen Shigella sonnei
Vibrio cholerae Pathogen Vibrio cholerae
Yersinia pestis Pathogen Yersinia pestis
In red bacteria from which GDP-L-synthase sequence has been compared with the human homologous.
Table S6. Sequence homology between human and bacterial GDP-L-fucose synthase peptides
A
GUT MICROBIOTA (MS) 51- T A Q T R A L F E K V Q P T H -65 % 136- P H N S N F G Y S Y A K R M I -150 % 161- Y G C T F T A V I P T N V F G -175 % 251- E E D E V S I K E A A E A V V -265 %
Blautia Blautia obeum Q D A V E K F F A T E K P E Y 13.33 L E K T N E A Y A L A K I S G 26.67 Y G D D F I S C M P T N L Y G 46.67 T G K E L T I K E L T E L V A 40.00
Clostridium sp. Clostriudium sp. KLE1755 Q A Q V R D F F E K E R P D V 46.67 L E E T N E A Y A I A K I A G 26.67 Y G D D F I S C M P T N L Y G 46.67 T G K E I T I K E L A E T V R 46.67
Lachnospiraceae Lachnospiraceae bacterium 3-1 Q A Q V T A F F E D E K P D V 33.33 L E A T N E A Y A I A K I A G 26.67 Y G D D F I S C M P T N L Y G 46.67 T G K E V T I R Q L A E T V Q 40.00
Blautia Blautia wexlerae Q D A V E K F F A T E K P E Y 13.33 L E K T N E A Y A L A K I S G 26.67 Y G T D Y I S V M P T N L Y G 46.67 T G K E L T I K E L T E L V A 40.00
Akkermansia muciniphila Akkermansia sp KLE 1798 P A A V R E F F D R E K P E Y 26.67 L E Y T N E P Y A I A K I A G 26.67 Y G A N Y I A V M P T N L Y G 53.33 T G K E I S I R G L A E L I A 33.33
Akkermansia sp KLE 1797 P A A V R E F F D R E K P E Y 26.67 L E Y T N E P Y A I A K I A G 26.67 Y G A N Y I A V M P T N L Y G 53.33 T G K E I S I R G L A E L I A 33.33
Akkermansia sp KLE 1605 P A A V R E F F D R E K P E Y 26.67 L E Y T N E P Y A I A K I A G 26.67 Y G A N Y I A V M P T N L Y G 53.33 T G K E I S I R G L A E L I A 33.33
Akkermansia sp CAG:344 P A A V R E F F D R E K P E Y 26.67 L E Y T N E P Y A I A K I A G 26.67 Y G T N Y I A V M P T N L Y G 53.33 T G K E I S I G D L A R L I A 26.67
Bacteroides fragilis G A A V K Q F F D E E M P E Y 20.00 L E Y T N E P Y A I A K I A G 26.67 Y G T N Y I A V M P T N L Y G 53.33 T G K E I T I R E L A G L I V 33.33
Bacteroides stercoris G V A V R R F F D E E Q P E Y 26.67 L E Y T N E P Y A I A K I A G 26.67 Y G T N Y I A V M P T N L Y G 53.33 T G K E I T I R R L A E L I V 33.33
Parabacteroides distasonis Parabacteroides distasonis Q A A V N E F F A A E R P D Y 20.00 L E Y S N E P Y A I A K I A G 33.33 Y G T N Y I A V M P T N L Y G 53.33 T G I E L S I R E V A E L I R 40.00
PATHOGENS
GUT MICROBIOTA (NO MS) 
Enterococcus faecium Q D A V E A F F A Q E K P D Y 20.00 L E K T N E A Y A L A K I S G 26.67 Y G T D Y I S V M P T N L Y G 46.67 T G K E L S I K E L T E M V A 46.67
Escherichia coli S R A V H D F F A S E R I D Q 6.67 L E P T N E P Y A I A K I A G 26.67 Y G R D Y R S V M P T N L Y G 46.67 T G V D C T I R E L A Q T I A 20.00
Helicobacter pylori K D N V Q A Y L K E Y K P T G 20.00 L E L T N E G Y A L A K L S V 33.33 K G V F Y K T L V P C N L Y G 26.67 S G V D Y S I E E Y Y E K V A 33.33
Klebsiella pneumoniae A Q D V N N F F A N E R I D E 6.67 L E S T N E P Y A I A K I A G 26.67 Y N R D Y R S V M P T N L Y G 40.00 T G V D C S I K E L A E T I S 40.00
NO GUT MICROBIOTA
Campylobacter jejuni Q Q A V I E F F K N E Q P E Y 20.00 L E Y N A T S F G V A K I S G 13.33 Y G T N F I T L A L N N L Y G 33.33 T G I D Y S I A E V A Q M V K 33.33
Mycobacterium avium R A K T F D F V L E S R P Q V 20.00 L E S T N D A Y A I A K I A G 26.67 Y G L A W I S A M P T N L Y G 40.00 T G V D H T I R E I A E M V A 33.33
Mycobacterium tuberculosis R A A T F D F V L E S R P Q V 20.00 L E P T N D A Y A I A K I A G 26.67 H G L P W I S A M P T N L Y G 33.33 T G I D H T I G E I A E M V A 33.33
Porphyromonas gingivalis A V A V R E F F D K E E P Q Y 26.67 L E Y T N E P Y A I A K I A G 26.67 Y G T N Y I A V M P T N L Y G 53.33 T G E E I S I R D L A S L I A 26.67
Pseudomonas sp P A A V Q A Y F A R H R V D Q 20.00 L E P T N E P Y A V A K I A G 26.67 H G R D Y R S V M P T N L Y G 40.00 T G V D C T I A E L A Q A L V 33.33
Salmonella enterica G R A V Q A F F A G A G I D Q 13.33 L E P T N E P Y A I A K I A G 26.67 Y G R D Y R S V M P T N L Y G 46.67 T G V D C T I R E L A Q T I A 20.00
Shigella sonnei S R A V H D F F A S E R I D Q 6.67 L E P T N E P Y A I A K I A G 26.67 Y G R D Y R S V M P T N L Y G 46.67 T G V D C T I R E L A Q T I A 20.00
Vibrio cholerae Q K A V N A F F A T E R I D E 13.33 L E A T N E P Y A I A K I A G 26.67 Y G R D Y R S V M P T N L Y G 46.67 T G V D C T I R E M A E T M A 26.67
Yersinia pestis Q S A V Q K F F A T E K I D E 6.67 L E P T N E P Y A I A K I A G 26.67 Y G R D Y R S V M P T N L Y G 46.67 T G V D C T I R E L A E T M A 26.67
Shigella flexneri S R A V H D F F A S E R I D Q 6.67 L E P T N E P Y A I A K I A G 26.67 Y G R D Y R T V M P T N L Y G 46.67 T G V D C T I R E L A Q T I A 20.00
% - percentage of identidal amino acids. In red are identical amino acids. Identical peptide shared by different bacteria has the same cell color.
B PEPTIDE	  1 Y G D D F I S C M P T N L Y G
PEPTIDE	  2 Y G T D Y I S V M P T N L Y G
PEPTIDE	  3 Y G A N Y I A V M P T N L Y G
PEPTIDE	  4 Y G T N Y I A V M P T N L Y G
PEPTIDE	  5 Y G L A W I S A M P T N L Y G
PEPTIDE	  6 Y G R D Y R S V M P T N L Y G
PEPTIDE	  7 H G R D Y R S V M P T N L Y G
PEPTIDE	  8 Y G R D Y R T V M P T N L Y G
Table S7. Demographical and clinical characteristics of MS patients and non-MS controls
Post-mortem Disease Duration 
sex age cause of death time (h) MS type (years) Block Type
MS Patients
MS 1 F 56 Breast carcinoma, Pneumothorax 8 SPMS 31 6 GM
MS 2 F 58 Peritonitis, inflamed caecal diverticulum 16 PPMS 22 9 WM
MS 3 F 78 Myocardial infection, acute abdomen 18 SPMS 33 1 WM
MS 6 F 58 Bronchopneumonia 6 PPMS 21 7 WM
MS 8 M 40 Dehydration / Multiple Sclerosis 18 SPMS 23 1 WM
3 WM
MS 14 F 78 Lung infection 9 PPMS 47 2 GM
MS 15 F 51 Multiple Sclerosis 15 SPMS 21 2 WM
MS 23 F 78 Metastatic carcinoma of bronchus 5 SPMS 42 1 WM
5 GM
MS 28 F 54 Bronchopneumonia 22 SPMS 20 1 WM
MS 32 F 39 Bronchopneumonia 18 PRMS 21 3 GM
MS 40 M 40 Respiratory failure, sepsis 10 SPMS 9 5 GM
MS 47 M 37 Intestinal obstruction 12 PPMS 27 2 GM
MS 51 F 49 Bronchopneumonia 12 PPMS 27 2 WM
Non-MS Controls
Non-MS 15 M 64 Cardiac failure 18 5 WM
Non-MS 18 M 35 Carcinoma of the tongue 22 3 GM
Non-MS 21 M 75 Aspiration pneumonia 17 1 GM
2 WM
Non-MS 28 F 60 heart failure, heart mestastasis 21 2 GM
1 WM
Non-MS 39 M na. Acute cardial death 10 5 GM
Non-MS 46 M 68 Metastatic colon cancer 10 1 GM
Non-MS 30 M 69 pericardial tamponade 7 1 GM
Brain Tissue
